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Abstract
Biochemical Characterization of the Release of FAK Autoinhibition
Jessica E. Hall
Focal adhesion kinase is an essential nonreceptor tyrosine kinase that plays an important role in
development, in homeostasis and in the progression of human disease. Multiple stimuli activate
FAK, which requires a change in structure from an autoinhibited to activated conformation. In the
autoinhibited conformation the FERM domain associates with the catalytic domain of FAK and
PI(4,5)P 2 binding to the FERM domain plays a role in the release of autoinhibition, activating the
enzyme. This work aims to better characterize the residues involved in the release of the
autoinhibitory conformation. The first aim was to characterize the effects of point mutations found
in the COSMIC database. None of these mutations had an impact on the FAK autoinhibited
conformation, thus classifying FAK as a kinase in which overexpression, and not mutation, is the
mechanism by which its activity is increased in cancer. The second aim was to assess the role of
FERM domain basic residues at the interface of the FERM and kinase domains in the autoinhibited
conformation, R184, K190, and K191. While mutation of these residues does not cause a significant
shift in FAK conformation, the results do suggest a minor role in binding to the membrane through
PI(4,5)P 2 and interacting with the kinase domain to maintain the autoinhibited conformation. The
third aim was to characterize residues on the catalytic domain that were modeled binding with the
membrane in silico. Constructs with these residues mutated to alanine exhibited defects in
phosphorylation and failed to completely rescue the phenotype associated with fak

-/-

phenotype

fibroblasts demonstrating the importance of these residues in FAK function. The catalytic domain
of FAK exhibited PI(4,5)P 2 binding in vitro and binding activity was lost upon mutation of putative
PI(4,5)P 2 binding site basic residues. Collectively, these studies further characterize the structural
elements that aid in maintenance of both the open and autoinhibited conformations of FAK.
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Chapter 1: Literature Review
Introduction
Focal adhesion kinase (FAK - also known as Protein Tyrosine Kinase 2 [PTK2]) is an essential
non-receptor tyrosine kinase. FAK localizes to focal adhesions (FA) and there plays a pivotal role
in the signaling at these specific sites and beyond. As a kinase an important role for FAK is
phosphorylation of downstream substrates to transmit cellular signals. FAK has an additional
function as a scaffolding protein and playing an integral part in the assembly of signaling
complexes. Both catalytic and scaffolding activities are critical for biological function. Multiple
extracellular stimuli regulate the activation of FAK. FAK is activated through integrin signaling,
but is also activated in response to stimulation of growth factor receptors, cytokine receptors, and
mechanical stimulation.
Given the broad range of stimuli that activate this kinase, it is not surprising that it controls
important and general cell phenotypes. Physiologically, expression of the FAK gene is essential as
fak-/- mice die during in the early stages of embryonic development.

FAK is important for

maintenance of healthy tissues and has roles in human pathology. The best example is the
significant role that FAK plays in cancer, where its functions in regulating tumor growth and
metastasis make it a key target for new cancer therapies.
Considerable structural information about FAK is available. NMR and/or crystal structures
of the three major domains have been determined. These structures have provided important
insight into the structural regulation of catalytic activity as well as insight in to the binding of
various proteins to FAK, and its scaffolding function. This literature review will sum up the
important research that has defined FAK’s structure and function in both healthy and diseased
states.

1

Biological and Physiological significance of FAK
FAK in Development
FAK is essential for multiple stages of development. FAK deficient mouse embryos do not
develop past the embryonic day 8.5 despite normal implantation [1]. Recent studies indicate that
FAK signaling is important prior to implantation as well.

FAK signaling is involved in the

maturation of cumulus-oocyte complexes prior to fertilization and plays a role in the maturation
into a healthy embryo [2]. Once the egg is fertilized, FAK is necessary for early embryonic cleavage
and the coordinated cell movements during embryonic morphogenesis known as epiboly [3,4]. In
X. laevis, FAK is required for tension dependent cadherin adhesion complex formation, which is
necessary for mass cell migration during gastrulation [5].
FAK is expressed throughout the embryo, but its expression is highest in the mesoderm.
Unsurprisingly, lack of FAK expression leads to mesodermal defects. FAK deficient embryos do not
properly develop a head fold nor neural tube nor heart tubes [1]. Through cell type specific
knockouts, FAK’s role in later developmental stages of various tissues has been determined. Miouse
embryos with endothelial specific FAK knockout die between embryonic days 9.5 and 11.5,
indicating the importance of FAK in the development of the vasculature [6,7]. Normal
vasculogenesis occurs in the absence of FAK, however embryonic angiogenesis fails resulting in
lethality. There is disagreement regarding the cellular defect responsible for this lethal phenotype.
Defects in proliferation and survival are reported in one knockout mouse line, while defects in
spreading and migration are attributed to the phenotype in the other model [6,7].
Several studies show that FAK is important for cardiac development in addition to the
development of the vasculature. In Xenopus laevis, FAK is essential for the development of a
multichambered heart through enabling the proliferation of myocytes necessary for chamber
outgrowth and facilitating the looping morphogenesis of the heart tube [8]. In mice, FAK is integral
2

for the proper alignment of the outflow tract and development of the aortic arch [9,10]. FAK is
essential for proper cardiomyocyte migration and proper development of the septum between
ventricles. FAK and a naturally occuring dominant negative variant which lacks catalytic activity,
FAK related non-kinase (FRNK), function in coordination to regulate the different stages of cardiac
development.

Through transient expression, FRNK facilitates cell cycle withdrawal of

cardiomyocytes allowing them to terminally differentiate [11]. A conditional knockout of FAK in
neural crest cells also causes a cardiovascular defect, in addition to craniofacial malformations. This
study shows that FAK is imperative for the differentiation and motility of neural crest cells and
suggests that a defect in FAK signaling may be associated this congenital defects [12].
FAK also functions in the developing nervous system to control multiple processes
including neuronal migration, morphogenesis and myelination. FAK signaling influences anteriorposterior cell fate in the developing neural plate [13]. In Xenopus laevis, phosphorylated FAK is
localized to neuronal growth cones and supports axonal pathfinding [14]. The process of axonal
pathfinding is aided through netrin signaling in which FAK plays a role. FAK is necessary for the
correct formation of axonal pathways, as it is a negative regulator of axonal branching and synapse
formation [15]. More recently the role of FAK in netrin mediated axonal guidance was confirmed
utilizing shRNA in primary mouse neurons [16]. FAK potentially inhibits cofilin activity, thus
regulating dendritic spine formation [17]. A combination of conditional oligodendrocyte-specific
and inducible FAK-knockout mice were used to investigate the role of FAK in myelination. This
study found that FAK is involved in the early stages of nuerological development. FAK controls the
efficiency and timing of CNS myelination during its initial stages by regulating the outgrowth and
remodeling of oligodendrocyte process [18]. As the neural tube closes, there is a large burst of cell
expansion which FAK is partly responsible for [19]. FAK in neuroepithelium triggers rapid growth
by a mechanosensory response to elevated pressure from the increase in cerebral spinal fluid [20].
3

Additional organ systems are also impaired by loss of FAK expression. FAK is essential for
the differentiation of osteogenic cells through a mechanosensory mechanism [21]. FAK signaling
also controls proper nephron tubulogenesis in the kidney [22]. These studies show the role played
by FAK in the development of multiple organ systems and that its signaling may impact multiple
areas of the body.

FAK in the Maintenance of Tissue
Past fetal development, FAK is important for the remodeling and maintenance of adult
tissues. FAK activity is vital for proper wound healing. Keratinocyte specific FAK knockout show
decreased healing. Furthermore, intestinal epithelial conditional FAK knockout mice show FAK’s
importance in maintaining an intact mucosa [23,24]. FAK is also necessary for stress related
responses prior to ischemia and healing after the injury. FAK myocyte knockout mice lack the
cardioprotective signaling triggered by ischemic preconditioning [25]. A kidney specific FAK
knockout model using an ischemia/reperfusion injury model shows that FAK is required for renal
tissue wound healing [26].
Beyond wound healing, adult tissues also need to remodel in response to changing
conditions. FAK continues to be important in this scenario as well. Inducible endothelial cell FAK
knockout shows that FAK plays a role in the maintenance of blood brain barrier integrity [27]. A
different endothelial FAK knockout model identified its importance in angiogenesis. However, the
same study also showed that the related protein Pyk2 can compensate in some scenarios [28].
Mammary epithelial specific FAK knockout leads to insufficient mammary gland development
during pregnancy [29]. FAK also plays a role in several stages of spermatogenesis as well as
maintenance of the blood testes barrier [30,31]. Overall, these studies show that FAK expression
and activity are essential to the proper function and maintenance of many tissue types in an adult
organism.
4

FAK in Cellular Function
FAK has three major functions in the cell: controlling survival, proliferation, and motility.
FAK contributes to survival signaling through a variety of pathways. Integrin signaling is imperative
for a cell to sense it is adherent and in the correct location relative to other cells in a tissue, and
should avoid a specific form of apoptosis, known as anoikis. FAK transmits integrin signals
necessary for prevention of anoikis through a number of different signaling pathways [32,33].
Integrin signaling also promotes cell cycle progression in response to mechanical stimulation.
FAK’s mechanosensory role helps to regulate adhesion responsive proliferation signals [34].
Interactions with growth factor receptors by FAK also encourage survival, proliferation and
motility through a variety of mechanisms. IGF1R can interact with and activate FAK leading to
antiapoptotic signaling [35]. FAK activation in response to EGF and PDGF induces cell proliferation
and migration [36]. Additionally, the HGF (scatter factor) receptor Met interacts with FAK directly
through phosphotyrosines and leads to increased cell invasion [37–39]. It seems that FAK is a hub
at which multiple growth factor receptor signals can be received and disseminated.
FAK also plays an integral role in the regular function of the cytoskeleton. It controls
turnover at focal adhesions through interactions with GAPs and GEFs involved in the regulation of
Rac and Rho [40]. FAK associates with 2 GAPs; GTPase regulator associated with FAK (GRAF) and
PH and SH3 domain containing Rho GAP (PSGAP); as well as two GEFs; RD2RhoGEF and
p190RhoGEF, that all regulate the activity of Rho [41–44]. FAK also regulates cytoskeletal
remodeling and actin polymerization through interactions with actin binding proteins Arp2/3 and
N-WASP [45,46]. This control of actin, Rho and focal adhesion turnover rate lead to FAK’s integral
role in cell motility [47]. Forming new adhesions and dissolving old ones are key steps cell
migration, and remodeling the cytoskeleton to reposition the cell mass over these adhesions is
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necessary as well. In addition to coordination of adhesions and the actin cytoskeleton, FAK can play
a role in directional persistence and mechanosensing [40,48].
Studies out of the Lim lab suggest an additional FAK function. In experiments reexpressing
the N terminal portion of FAK they observed nuclear localization [49,50]. Follow up studies with
full length FAK showed similar results [50]. This localization can impair the transcription of certain
genes through interaction with the N-terminal transactivation domain of p53 [51,52]. Furthermore,
FAK influences the overall structure of chromatin through binding of Methyl-CpG Binding Domain
Protein 2 (MBD2) and inhibiting the action of MBD2 as a transcriptional regulator [53]. These
observations may explain the effects of FAK on gene regulation and expression to promote survival
and proliferation.

FAK in Human Disease
Cancer
Studies examining the role v-src oncogene and its tyrosine kinase in oncogenic
transformation of fibroblasts led to the discovery of FAK as a substrate for v-src [54]. FAK was also
independently isolated as a tyrosine kinase expressed in breast carcinoma [55]. While two other
groups also independently identified FAK in other contexts [56,57], the two discoveries in the
context of cancer suggested a potential role in oncogenesis and many studies have now confirmed
the role of FAK in the development and metastatic spread of cancer. This conclusion is based upon
three major observations: 1) FAK is overexpressed in many cancers, 2) aberrant FAK expression in
some cancers is associated with poor prognosis, and 3) perturbation of FAK in a number of animal
models blocks tumorigenesis and metastasis.
Initial studies to examine FAK in human cancer identified elevated FAK expression at the
protein or RNA level in a variety of different tumor types. Interestingly, in melanoma elevated
phosphorylation of FAK without overexpression was observed [58]. In a number of tumors, FAK
6

expression was elevated in advanced metastatic disease, and in melanoma elevated phosphorylation
was observed in metastatic but not primary tumors. These findings originally suggested that FAK
might be associated with advanced disease. However, other studies have demonstrated that
elevated FAK expression in early stages of cancer and thus is not strictly associated with advanced
stages of cancer. In some types of cancer, FAK overexpression is prognostic. For example, FAK
overexpression in ovarian cancer and esophageal squamous cell carcinoma is associated with poor
outcome [59,60]. In breast cancer, FAK overexpression has not been linked to prognosis but,
amplification of the FAK gene is a poor prognostic indicator [61]. Not all studies have demonstrated
a link between FAK expression or phosphorylation and disease outcome. Further analysis of some
of these cancers might be warranted since the linkage of FAK expression to outcome may be more
complex. For example, FAK overexpression is not prognostic in laryngeal cancer and neither is loss
of E-cadherin expression. However, if FAK expression and E-cadherin expression are considered
together they do serve as prognostic indicators. Patients with tumors exhibiting elevated FAK
expression and low E-cadherin expression exhibit significantly reduced survival [62]. These
examples demonstrate FAK overexpression, amplification, or phosphorylation are important in
many tumor types and in some, but not all cases, this is indicative of poor prognosis.
Many experimental models have been employed to evaluate the role of FAK in
tumorigenesis and metastasis. Anti-sense, dominant negative and RNA interference strategies have
been employed to investigate the role of FAK in xenograph and orthotopic tumor models and an
experimental model of metastasis. The results of these studies have implicated FAK in regulating
the tumorigenic and metastatic properties of both murine and human cell line models of cancer,
like in breast cancer models [63,64] and ovarian cancer models [65]. Since the FAK knockout is
embryonic lethal, conditional knock out approaches were used to evaluate the role of FAK in
additional animal models of cancer. In a chemical carcinogenesis model of skin cancer, FAK was
7

implicated both in the formation of papilloma and progression to carcinoma [66]. In transgenic
models of breast cancer, multiple groups have demonstrated a role for FAK in tumor formation and
metastasis [61,67,68]. These studies establish an active role for FAK in controlling tumor formation
and metastasis in animal models.
Cardiac Disorders
While FAK is involved in several steps in the development of cardiovasculature and may
play a role in congenital defects, it also is implicated in cardiac disorders developed later in life.
FAK is highly expressed in cardiomyocytes and is activated by both mechanostimulation, as well as
angiotensin II and endothelin [69].

It is expressed in register with myofilaments near the

sarcomeric A Bands but under stress FAK translocated to the Z discs of cardiomyocytes [70].
Because of its unique localization and activation in cardiomyocytes several groups have looked in
to FAK’s role in cardiac remodeling. In cell culture FAK is necessary for hypertrophic responses
[71,72]. Cardiomyocyte FAK knockout mice showed that FAK is necessary for cardiac hypertrophy
in response to stress [73]. It is interesting to note that a later study corroborated the need for FAK
in stress response, but showed that it is not necessary for cardiomyocyte maintenance [74].
While some hypertrophic growth is a necessary stress response, FAK has been implicated
in the hypertrophic maladaption that leads to diastolic heart failure [75]. In comparisons of hearts
from patients an increase in FAK expression and phosphorylation was detected in hearts with
diastolic heart failure [76]. Mouse models agree with these findings, and siRNA knockdown of FAK
can partially rescue heart failure [77]. Additional studies utilizing a cardiomyocyte specific
transgenic strategy, suggest that FAK controls hypertrophic growth by activating both the AKT and
mTOR pathways [78].

The mechanism by which FAK is regulated in cardiomycytes and in

hypertrophic growth signaling is unclear. The interaction of sarcomeric myosin with the FAK

8

FERM domain was established by small-angle x-ray scattering and this interaction negatively
influences hypertrophy [79].
FAK is also expressed in the vascular endothelium as well as vascular smooth muscle cells.
The response of FAK to mechanical stimulation as well as to growth factor signaling implicates it
in hypertension and atherosclerosis. Sheer stress in the vasculature can activate endothelial cell
FAK [80]. VEGF stimulation of FAK enables endothelial remodeling [81]. Additionally, FAK is
needed for vascular smooth muscle cell repositioning in the eutrophic remodeling response to
hypertension [82]. Along with changes in the vasculature, FAK plays a role in the signaling and
immune response at atherosclerotic plaques. Endothelial FAK/RSK signaling in response to
oxidized LDL is needed for leukocyte recruitment and early atherosclerosis [83]. FAK knockdown
mice show reduced endothelial cell permeability, suggesting that FAK activation could also increase
the leukocyte population at atherosclerotic plaques. Macrophage response to plaques is a necessary
step in atherosclerotic progression and FAK signaling is necessary for macrophage motility [84].
These studies show that FAK could be a potential target in the treatment of atherosclerosis.

The Other Family Member: Pyk2
There is one other member of the FAK family.

Protein Tyrosine Kinase 2 (Pyk2) is

structurally very similar to FAK, however its role in the cell is very different. Pyk2’s nucleotide
sequence is 46% identical to FAK, its amino acid sequence is 65% similar and exhibits the same
domain organization and the structural characteristics as FAK. Like FAK, the Pyk2 gene also
encodes an inhibitory splice variant [85].
Pyk2 is activated in response to growth factors and cytokines. Pyk2 is activated by an
increase in cytoplasmic Ca2+ from stimulation by a ligand such as vasopressin or PDGF that triggers
the Phospholipase C pathway [86]. While pyk 2 has a generally cytosolic localization, it Pyk2 plays
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a role in regulation of the cytoskeleton during cell repulsion, as well as cell attachment and
spreading in osteoprogenetor cells [87,88].
Pyk2 has a significantly different role in development as compared to FAK. Pyk2 is more
restricted in its expression and function during development and Pyk2 -/- mice are fertile and
exhibit no visible malformations [89]. However, these mice do exhibit some deficits in the immune
system. The Pyk2 -/- mice have a reduced number of Marginal Zone B cells (found in the marginal
zone of the spleen) and mount a defective humoral immune response [89]. Pyk2 null CD8 positive
T cells are not properly activated in response to T cell receptor and LFA1 co-stimulation [90]. The
macrophages and osteoclasts in Pyk2 -/- mice are also defective. The macrophages show reduced
infiltration toward inflammatory stimuli in vivo and exhibit polarization, contractility and motility
defects in vitro [91]. Pyk2 -/- osteoclasts produce an abnormal sealing zone and a defect in bone
resorption, leading to osteoporosis [92]. Interestingly, a second group attributes the increased bone
mass in Pyk2-/- mice to increased osteoblastogenesis and osteoblast activity, rather than differences
in osteoclast activity [93]. Finally Pyk2-/- mice are also more prone to obesity and insulin resistance
[94]. Overall, while FAK and Pyk2 are structurally very similar their functions do not significantly
overlap. Pyk2 does pose an interesting target in understanding osteogenic diseases but with FAK
playing a role in cancer and cardiac diseases, the two of the biggest factors in American mortality,
it is the more significant research topic.

FAK Structure: A Multidomain Puzzle
The key to understanding the function and regulation of any protein is understanding its
structure and how interacting proteins and ligands interact with that structure (Figure 1). The
identification of domains within FAK was originally made based upon sequence homology and
deletion analysis to identify functional regions of the protein. The general structure of FAK is very
simple. There are four domains arranged in a linear fashion. The N terminus consists of the band
10

4.1, Ezrin, Radixin, Moesin (FERM) domain followed by the Kinase domain. These two domains are
separated from the C terminal focal adhesion targeting (FAT) domain by an unstructured proline
rich region [103].
FAK becomes phosphorylated at several sites [104,105]. Tyr 397 lies within the linker region
between the FERM and kinase domains, and it is the major autophosphorylation site [106]. This
site is also the site necessary for Src binding [105]. Tyr 577, 576, 861 and 925 are also key residues
that are phosphorylated by Src. Tyr 576 and 577 are in the activation loop of the kinase domain and
phosphorylation promotes maximal catalytic activity. In addition to tyrosine phosphorylation,
several serine residues are phosphorylated in FAK. Phosphorylation of Ser 722 is regulated by GSK3
and the PP1 phosphatase and has an inhibitory effect on FAK catalytic activity [107]. Ser 732 is
phosphorylated by Cdk5 and is essential for actin cytoskeletal reorganization, neuronal migration
and centrosome function in mitosis and during neuronal migration [108–110].

Thus serine

phosphorylation of FAK is as physiologically significant as tyrosine phosphorylation, and both types
of phosphorylation can regulate FAK catalytic activity and scaffolding functions.
FAK Related Non Kinase (FRNK), is a naturally occurring splice variant of FAK consisting
of solely the C-terminal portion consisting of the proline rich region and FAT domain. FRNK
functions as a dominant negative mutant to block FAK function [111–113]. The FRNK Transcript is
initiated from a second promoter within the FAK gene [114]. FRNK consists of the C terminal
proline-rich and FAT domains of FAK and is missing the FERM and Kinase domains. The dominant
negative function is through competition with FAK for localization to focal adhesions and possibly
by titrating away FAK binding partners important for function [115]. FRNK has frequently been
used as an experimental tool to evaluate the role of FAK in controlling biological function, but also
is a physiological regulator of FAK, for example during cardiac development [11].
FERM Domain
11

Band 4.1, ezrin, radixin, moesin (FERM) domains are tri-lobed, typically N terminal domains
[116]. They are commonly found in proteins that bind cytoplasmic regions of transmembrane
proteins and often act as linkers between the cytoskeleton and plasma membrane. In addition to
intermolecular interactions, FERM domains frequently mediate intramolecular interactions. The
ezrin, radixin and moesin FERM domains each bind their C-terminal domains [117]. Amino acid
sequence analysis showed both FAK and Pyk2 have N-terminal FERM domains, though the FAK
family FERM domains share only 12-15% identity with the sequences of other FERM domains [118].
Crystal structures of the FAK FERM domain alone, and in complex with the catalytic domain are
solved and provide considerable insight into FAK regulation and function [119,120].
Like all FERM domains, the FAK FERM domain has three lobes, the F1, F2, and F3
subdomains. The F1 subdomain spans residues 33 – 127 and consists of a five strand β sheet capped
by an α helix. This subdomain exhibits an ubiquitin like fold. It has several structural features that
differ from the F1 subdomains of other FERM domains. The second α helix is longer than in most
FERM domains, and the β1 – β2 and α2 – β5 loop regions are also longer. In FAK, these loops contain
3 10 helices, a feature unique among the FERM domain containing proteins [119]. Each of these
features are on the surface of the domain where structural differences could impact interactions
with other proteins. The F2 subdomain spans residues 128-253. The structure is entirely α helical,
containing 4-core helices. This helical core is similar to that found in the acyl-CoA-binding protein
[119]. There are several unique features of the F2 subdomain. It has three segments containing 3 10
helices and a nine residue α2’ helix located between the α2 and α3 regions. This region of the
protein forms a surface that docks with the catalytic domain. The F2 subdomain also contains a
basic patch on the apex of the domain that plays a significant role in FAK regulation. This patch
contains the sequence

KAKTLRK222 that is important for phosphatidylinositol and
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phosphotyrosine binding [121,122]. As they play a role in contact with the catalytic domain and
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ligand binding, these two features mark the F2 subdomain as a key regulator of autoinhibition,
unique among FERM domains. The final subdomain covering residues 254 to 352 is the F3
subdomain. It is a β sandwich capped with a C terminal α helix. This structure resembles a PH
(pleckstrin homology domain), a PTB (phosphotyrosine binding) domain and an EVH1 (Ena/VASP
Homology) domain. This structural similarity suggest a role in protein binding. However, the
surface features are different on the surface of the FERM domain. So the F3 subdomain of FAK
lacks the structural features of PH domains required to bind acidic phospholipids and the features
of PTB domains required to bind tyrosine phosphorylated peptides.
Taken individually the subdomains of the FAK FERM domain are quite similar to those from
other FERM containing proteins. The orientation of the individual subdomains in relation to each
other is a little bit different. The ERM proteins, such as radixin, have a very symmetrical
arrangement of the three domains leading most ERM family members to structurally overlap each
other with a root mean square of less than 1 Å. FAK FERM aligns with radixin with a root mean
square around 1.5 Å, due to a shift of the domains in relation to each other. The most noticeable
shift is in the orientation of the F3 subdomain. It is rotated in such a way that the α1 helix is closer
to the F1 subunit than in other FERM domains. The FERM domains of the ERM proteins have a
phosphatidylinositol binding site in a shallow basic cleft between F1 and F3. In the FAK FERM
domain the sequences between the F1 and F3 domains are not basic, the cleft between the two
domains is narrower and it is occupied by part of the linker between the FERM and catalytic
domains, thus precluding PI binding via this mechanism. What is especially interesting about the
FAK FERM domain is that while the potential for PI binding is occluded in the F1/F3 cleft, a basic
ridge on the F2 subdomain does bind to PIP2 [123].
The Linker
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The linker between the FERM and kinase domains is an unstructured region spanning
residues 352 to 415 and contributes to the structural distinctiveness of FAK FERM domain. The
portion of the linker proximal to the FERM domain forms an antiparallel β sheet that binds on a
groove on the F3 subdomain. The linker, in this position completely buries the site analogous to
the phosphatidyl inositol binding site on other F3 subdomains. Two important features of the
linker are Tyrosine 397, which is the major autophosphorylation site and Src SH2 domain binding
site and the nearby “PxxP” motif that acts as a binding site for the SH3 domain of Src [104].

Kinase Domain
The kinase domain of FAK has been crystallized in three states: with the activation
loop fully phosphorylated and bound to a non-hydrolysable ATP analog (fully activated
conformation) (PDB 2JOL), alone with an unphosphorylated activation loop (inactive
conformation) (PDB 1MQB), and unphosphorylated and bound to the FERM domain (autoinhibited
conformation) (PDB 2JOJ, 2JOK) [120,124]. These structures demonstrate that like the catalytic
domains of other protein kinases, the FAK Kinase is bilobed, with the N-terminal lobe containing
a single α helix (the C α helix) and a 5 stranded β sheet, and the larger C terminal lobe that is mostly
α helical. In FAK, the C α helix in the N lobe is rotated away from the C terminal lobe. The C α
helix is in the same position in the active and inactive conformations, indicating that C-helix
displacement is not a method of regulation of FAK [120]. In the unphosphorylated structures the
activation loop is disordered. In the phosphorylated structure the activation loop adopts the β
hairpin loop conformation seen in many other active kinases. In the unphosphorylated kinase
structure with no ATP analogue present, the ATP binding site was a network of ordered water
molecules, indicating a large amount of hydrogen bonding in the active site. The hydrophobic
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pocket that contains the adenine base on ATP is bordered by M499. Additionally, ATP binding has
been shown to create a small conformational change in the kinase domain, this could play a role in
the allosteric regulation of FAK [125].

One structure of the unphosphorylated kinase domain

contains a disulfide bond in the N lobe between cysteines 456 and 459 [124]. The cysteines are
conserved in vertebrate FAKs and a regulatory role for this bond was suggested, however, other
crystal structures do not contain this disulfide bond.
The crystal structure of the PYK2 kinase domain is very similar to that of the FAK kinase
domain [126]. The ATP binding pocket of the PYK2 kinase domain cradles adenine with residues
431, 455, 487, 504, and 556, and the interaction is stabilized by interactions between the amino
group and the N1 nitrogen with residues 503 and 505.
Proline-Rich Region
The Proline-rich region is an unstructured flexible region spanning residues 687 to 918.
While unstructured, this sequence contains several key scaffolding sites. First there are four “PxxP”
motifs, two that are well defined, PR1 (712PPKP715) and PR2 (872PPKKPP877), and two that were
recently identified in a study looking at cortactin interactions with FAK, PR3 (718PGYP721) and PR4
(879PGAP877) [127]. These motifs serve as binding sites for the SH3 domains of a number of proteins.
This study showed that interaction at PR3 with cortactin is necessary for FAK activation in response
to Helicobacter pylori infection [127]. They SH3 domain of Crk-associated substrate (p130Cas)
interacts with FAK at PR1, and this interaction is vital for proper regulation of FAK mediated cell
migration [128–130]. PR2 interacts with the SH3 domain of edophilin A2 and this interaction
promotes Src-dependent phosphorylation of endophilin-A2 and reduced endophilin-A2 dependent
endocytosis of MT1-MMP, leading to increased cell invasiveness [131]. GTPase regulator associated
with FAK (GRAF) also binds to FAK via SH3-mediated binding to PR2, and this interaction is
important for many Rho-based signaling events [41].
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Other GAPs and and GEFs incliding

p190RasGAP, Rgnef, and ASAP1 interact with PR1 and PR2. The PR motifs serve a scaffolding
function, the recruit multiple proteins, many of which regulate actin polymerization and FA
formation, thus these regions of FAK serve a critical role in the control of motility [132].
Phosphorylation sites are also key binding sites, especially for SH2 domain containing
proteins. The proline-rich region of FAK contains an abundance of serine phosphorylation sites, as
well as one threonine and one tyrosine phosphorylation site [133,134]. The functions of some of
these in scaffolding and signaling have been identified, while the role of others has yet to be
determined. Serine phosphorylation of the proline-rich region plays a significant role in the control
of cell cycle and mitosis by FAK [133]. Phosphorylation on Serine 722 is regulated by GSK3 and PP1
and phosphorylation at this site increases cell spreading [107]. Serine 732 is phosphorylated by
CDK5 [109]. This phosphorylation is linked to FAK localizing with the centrosome, microtubule
fork and cytoplasmic dynein [110].

This localization may lead to microtubule arrangement,

endothelial cell proliferation, and angiogenesis [108,135]. Tyrosine 861 has been long held as one of
the Src phosphorylation sites on FAK, though a less prominent one than those in the kinase
activation loop [136]. Phosphorylation of this residue has been linked to VEGF stimulated antiapoptotic activity and cell migration [137]. Recently though, its role in FAK activity has been
redefined. Using a modified Boyden chamber assay Chatterji et al, identified cells with increased
migration in two different prostate cancer cell lines [138]. These more motile cells had increased
Tyrosine 861 phosphorylation. An investigation of src family kinases (SFKs) in these motile
subclones lead to the conclusion that yes kinase expression was increased and that yes preferentially
phosphorylates tyrosine 861 [138]. Elevated yes expression and increased phosphorylation of FAK at
tyrosine 861 were also observed in metastatic tumors in human patient samples [138]. There is
much to be discovered regarding the roles of the phosphorylation sites in the proline rich region in
assembling protein complexes.
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FAT Domain
The FAT domain is the very C-terminal domain, and is responsible for FAK’s localization
to focal adhesions [139]. The efforts of a number of groups have yielded both crystal structures and
NMR solution structures of the FAT domain [140–143]. The domain contains four amphipathic
alpha helices that assemble into an antiparallel four helix bundle with an up-down-up-down righthanded topology. The crystal structure of the highly conserved FAT domain of Pyk2 has also been
solved and this domain adopts a similar fold [144]. There is similarity in the FAT domain structure
and the structures of the C-terminal vinculin tail, alpha-catenin and apolipoprotein 3, since all
contain a right-handed antiparallel four helix bundles [140].
The most noticeable features of the FAT domain of FAK are two hydrophobic patches on
the surface of the domain flanked by basic residues. One of these is at the interface of alpha-helices
1 and 4, and the other is on the opposite side of the molecule at the interface of alpha-helices 2 and
3. These hydrophobic patches were originally proposed as binding sites for FAK associated proteins,
which has been confirmed by crystallographic and NMR studies [103,145,146]. The two hydrophobic
patches of the FAT domain engage LD motifs of paxillin. The LD motif is a peptide motif repeated
multiple times in the N-terminal half of paxillin and the paxillin related proteins, leupaxin and hic5 [147,148]. The second and fourth LD motifs of paxillin function as FAK binding sites and each can
form an amphipathic alpha-helix. The hydrophobic surface of these LD motifs docks with the
hydrophobic patches of the FAT domain with acidic residues in the LD motifs interacting with the
basic residues surrounding the hydrophobic patches on the FAT domain. While the conserved
nature of the LD motifs and hydrophobic patches suggest interchangeable interactions, the docking
of a peptide mimicking the LD2 motif to each binding site on the FAT domain exhibits different
thermodynamic properties [103]. Several experimental approaches demonstrate a preference of the
LD4 motif for the hydrophobic patch formed at the interface of alpha-helices 2 and 3 in the FAT
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domain [146,149]. Similar interactions facilitate binding of LD motifs to the FAT domain of Pyk2
and the FAT homology domain of Git1 [150].
Tyrosine 925 in FAK and tyrosine 881 in Pyk2 are sites of phosphorylation and mutation of
these residues dramatically impairs recruitment of Grb2, a scaffolding protein that is important for
FAK signaling [151,152]. These tyrosine residues reside within alpha helix 1 of the FAT domain and
this structure makes them poor substrates for kinases and poor recognition motifs for the Grb2 SH2
domain, which both recognize tyrosines in an extended peptide conformation and not an alpha
helix [153]. Thus for efficient phosphorylation and Grb2 binding, a conformation change in the FAT
domain was proposed. One crystal structure of the FAK FAT domain revealed a domain swapped
dimer, where alpha helix 1 of two different molecules were exchanged to form a dimer [141]. While
this dimerization is not physiological, the result suggests conformational dynamics of the FAT
domain during expression, purification and crystallization.

Hydrogen exchange experiments

support the hypothesis that the FAT domain is a dynamic structure and discrete molecular
dynamics analysis of the FAT domain structure, guided by the results of hydrogen exchange, further
support the model that alpha helix 1 can be displaced to facilitate transition from a helical to
extended conformation of the peptide sequence containing tyrosine 925 [154,155]. These studies
suggest that the FAT domain is dynamic, capable of adopting the four helix bundle and an altered
conformation allowing phosphorylation of tyrosine 925 and Grb2 binding. Binding of the paxillin
LD motifs to the FAT domain, particularly to the interface of alpha helices 1 and 4, stabilizes the
four helix bundles and impairs tyrosine phosphorylation of these sites and Grb2 binding. Thus
paxillin binding might regulate FAK signaling by regulating FAT domain structure, promoting
specific signaling events while inhibiting others.
Autoinhibiton and the Activation of FAK
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The FERM domain was proposed as a negative regulatory element of FAK as deletion of the
FERM domain resulted in elevated catalytic activity and constitutive tyrosine phosphorylation in
cells [156–159]. Ezrin, radixin, and moesin all contain N-terminal FERM domains that regulate their
activity by creating contacts with and folding over the active sites of more C-terminal domains
[160].

Based upon autoinhibitory models of other ERM proteins, a similar autoinhibitory

mechanism was proposed for FAK in which the FERM domain folds over the active site of the kinase
domain. The first experiments supporting this mechanism utilized exogenous expression of the
FERM and kinase domains separately to show they interact in trans, and that this interaction has a
negative effect on functionality [161]. Additionally, expression of individual subdomains F1 and F2
inhibits tyrosine 397 autophosphorylation, indicating that these two subdomains are key for kinase
inhibition in FAK [162].
A fragment of FAK containing both the FERM and kinase domains was crystallized, and the
structure shows that the FERM and kinase domains do indeed interact (PDB 2JOJ). There are two
points of contact between the domains. The most extensive is between the F2 subdomain of the
FERM domain and the C-lobe of the kinase. This interaction leads to a 649 Å2 area of the kinase
domain being buried. This area is highly conserved among various species. This interaction is
critical for autoinhibition since mutation of a number of different residues within the buried area
creates constitutively active variants of FAK [120]. The second, less intimate, point of contact is
between the F1 subdomain and the N-lobe of the kinase through both domains making contact with
the linker region.

This interaction may also be important in stabilizing the autoinhibited

conformation, since mutation of Lys 38, an F1 subdomain residue that appears to interact with the
linker, results in a constitutively active mutant [162]. When the FERM domain is bound to the
kinase domain part of the linker rests against the F1 subdomain in an anti-parallel β strand
interaction. This keeps Y397 approximately 35 Å away from the catalytic cleft of the kinase domain,
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preventing intramolecular autophosphorylation. There are several splice variants of FAK that
create a longer linker region [163,164]. These variants show elevated phosphorylation and catalytic
activity [158]. Further, these variants may exhibit an altered mechanism of autophosphorylation,
via an intramolecular rather than trans phosphorylation mechanism that may be dependent on the
longer linker [158]. Destabilization of the autoinhibited conformation by the altered linker could
explain both constitutive activation and mode of autophosphorylation, although this hypothesis
has not been tested.
In crystal structures the activation loop of the kinase domain is disordered [120,124]. Based
upon the topology of the autoinhibited conformation, Y576 and Y577 are somewhere in the cleft
between the active site and the F1 and F2 subdomains of the FERM domain. In the crystal structure
of the phosphorylated, active kinase domain (2J0L), the phosphorylated activation loop takes on a
β hairpin conformation that is stabilized by hydrogen bonds and electrostatic interactions between
the phosphate group on pY577 and the back bone of S580 and A579, and the side chain of R569.
This same structure, the phosphoryilated activation loop, juts out from the kinase domain,
occupying the same space that the FERM domain is present in other crystal structures. This
suggests that activation loop phosphorylation can block FERM domain interactions with the
catalytic domain. Thus restoration of the autoinhibited state is dependent upon dephosphorylation
of the activation loop residues by cellular tyrosine phosphatases. Mutation two lysines to glutamic
acids within the activation loop creates a hyperactive mutant, consistent with a role for the
activation loop in promoting catalytic activity [165].
Full Length FAK: Putting it all together
While the various structured domains of FAK have been crystallized, the structure of the
full length FAK is still unknown. Because of the flexible regions, full length FAK is too flexible to
form suitable crystals and the full length protein is too large for NMR studies. Small angle x-ray
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spectroscopy (SAXS) studies have yielded some structural insights [166]. SAXS yields lower
resolution shapes of molecules or assemblies too large or unwieldy for higher resolution methods.
By matching the low resolution shapes from SAXS to the existing FERM domain crystal structures,
a FERM dimerization was suggested. Interestingly all existing crystals of the FERM domain contain
a similarly shaped FERM dimer [119,120,166]. Additionally, fitting the kinase and FAT domain
structures into the SAXS low resolution shape suggested that the FAT domain binds to the F2
subdomain, potentially stabilizing dimers, or holding the autoinhibitory conformation but
contacting both the FERM and catalytic domains [166]. Further studies showed that tryptophan
266 is necessary for FERM domain dimerization and FAK association occurs in vitro. Previous
studies suggested that transient dimerization was necessary for phosphorylation, which occurs in
trans [158].

The SAXS data combined with current knowledge about FAK activation and

autophosphorylation suggest that an inactive FAK is curled up upon itself with the FAT domain
and proline-rich region wrapped around the FERM-kinase autoinhibited complex. This compact
structure would need to unfold in response to activating signals.
F2 the Key to FAK Regulation?
One interesting thing about the SAXS model for full length structure is the dependence on
the F2 subdomain for FAT domain binding, more specifically the

KAKTLRK222 sequence [166].
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This sequence has also been shown to be necessary for FAK activation [123]. Additionally, this basic
patch is necessary for PIP2 binding and this interaction triggers FAK conformational change and
activation [122]. Further studies into lipid binding suggest that PI(4,5)P 2 interactions lead to FAK
FERM domain clustering in vitro [167]. The importance of the 216KAKTLRK222 sequence is further
highlighted by its interactions with receptor tyrosine kinases.

FAK’s interaction with the

hepatocyte growth factor receptor Met has been well characterized and depends again on this
sequence [38,121]. The GDNF receptor RET also binds to the FERM domain through this sequence,
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however this mechanism may differ from PI(4,5)P 2 and Met as unlike the other interactions
phosphorylation decreases the affinity of RET for FAK [168].
the

Overall these studies imply

KAKTLRK222 and the rest of the F2 subdomain are vitally important for release of
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autoinhibition.

Biosensors
Fluorescence resonance energy transfer (FRET) is a phenomenon in which energy is
transferred from one excited fluorescent molecule to another which then in turn emits light. This
phenomenon has a spatial constraint of 10 angstroms, making it a wonderful tool to investigate
molecular interactions. Two separate groups have created FRET based biosensors to measure
conformational change in FAK. The conformational biosensor made by the Schaller lab consists of
CFP on the N terminus of FAK and citrine at arginine 413 on the N lobe of the kinase. This places
the acceptor and donor across the linker from each other. This arrangement, while accurate in
indicating conformational change upon FAK activation, is less than ideal as activation, and
presumably the open conformation, leads to a reduction in FRET signal [122]. Another group
developed a different conformational biosensor which contains YFP at the N terminus of FAK and
a CFP inserted at valine 391 in the linker, switching the positions of the donor and acceptor
molecules for FRET. The change in fluorophore position is reported to lead to an increase of FRET
upon FAK activation in their reported findings, most likely due to a change in fluorophore dipole
position as opposed to a decrease in distance [169]. However, reproduction of this biosensor by
members of the Schaller lab shows a similar reduction of FRET signal upon activation as the
arginine 413 biosensor [Personal communication with W. Fu]. Because of the nature of FRET,
studies done thus far with conformational biosensors have not clarified the mechanism of
activation. The FERM and kinase domains could be pulles straight apart (domain straightening) or
could twist away from eachother (twisting switch) upon activation. Since FRET signal will decrease
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upon rotation of the fluorophores as well as an increase in distance, these biosensors may not be
the tool needed to determine this movement [122,169].
Two other FRET based biosensors have been developed to investigate Y397
phosphorylation. The first phosphorylation biosensor consists of a FAK molecule labeled on the N
terminus with CFP and a citrine labeled Src SH2 domain. Since phosphorylation of Y397 is
necessary for Src binding, increased FRET signal indicates phosphorylation [122]. This two molecule
biosensor allows for observation of FAK activation in a multi-protein context. Another group
developed a single molecule phosphorylation biosensor that does not contain full length FAK or
Src [170]. This biosensor has a high level of FRET when the Y397 peptide is unphosphorylated. It
consists of an ECFP followed by the Src SH2 domain; this is connected by a short linker to a peptide
containing the sequence of residues surrounding the FAK Y397 site and YPet.

When

phosphorylated, it binds to the SH2 domain moving the fluorophores away from each other,
decreasing FRET [170]. One advantage of this small phosphorylation biosensor is that it is a reliable
measure of endogenous FAK activity as Y397 is the autophosphorylation site. Additionally the
addition of other domains can target it to certain areas of the cell. For Example Lyn DRM-targeting
motif and K-Ras RGD motif have been added to observe FAK activation near lipid rafts, and the
FAT domain has been added to compare FAK activity in the cytosol versus focal adhesions [170,171].

FAK’s Place in the Ultra-Structure of Focal Adhesions
Recent experiments utilizing interfering photoactivatable light microscopy (iPALM)
clarified the ultrastructure of focal adhesion architecture [172].

This study revealed that focal

adhesions are ordered and stratified. Each layer of the stratification is proposed to play a different
role in focal adhesion function. FAK and paxillin exist in the layer closest to the membrane, defined
as the integrin signaling layer. The other layers are the force transduction layer containing tailin
and vinculin, and the actin regulatory layer containing zyxin and VASP. So far iPALM studies have
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only been conducted with an N terminally labeled FAK construct [172]. The fluorophore localized
to a very narrow range in the focal adhesions suggesting that the bulk of FAK molecules are
positioned in the same orientation. N and C terminal labels were utilized on Talin to confirm
orientation. It will be interesting to see where the C terminus localizes and if the localization
changes in response to activation.

Ligand interactions with the FERM domain of FAK
Growth Factor Receptors
A broad range of extracellular stimuli induce FAK tyrosine phosphorylation and activation,
including growth factors. FAK acts as a bridging adaptor protein that links growth factor receptor
and integrin signaling pathways to support cell motility. FAK is required in PDGF and EGF induced
cell migration, and the N-terminal 402 amino acids of FAK forms a complex containing activated
growth factor receptors [36]. Phosphorylation of FAK at Tyr397 is not required for the formation
of this complex; however the EGF receptor promotes FAK phosphorylation at Tyr397. Over
expression of FRNK disrupts the interaction of FAK with activated EGF receptors. Since FRNK is
missing the FERM domain, cell adhesion dependent activation of FAK may be required for
interaction with these growth factor receptors. Despite its conservation of sequence, PyK2 does
not associate with these activated growth factor receptors [36,173].
A recent study suggests a unique mechanism for interaction between EGFR and FAK
utilizing a splice variant of Steroid Receptor Coactivator 3, SRC-3Δ4, which binds to steroid
receptors

and

stimulates

transcriptional

activity

[174].

Endogenous

SRC-3Δ4

co-

immunoprecipitates with FAK and the EGF receptor. SiRNA mediated knockdown of SRC-3Δ4
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partially reduces the co-immunoprecipitation of EGF receptor with FAK, suggesting that SRC-3 Δ4
may mediate this interaction, although there may be additional molecular mechanisms of
interaction between the two kinases. Interestingly, serine and threonine phosphorylation of SRC3Δ4 by PAK is required for binding to both EGFR and FAK. The proposed EGFR/ SRC-3Δ4/FAK
complex seems important for cell migration in vitro and metastasis in vivo.
The Met receptor mediates hepatocyte growth factor (HGF) signaling in cells. Stimulation
of cells with HGF promotes FAK tyrosine phosphorylation [39]. The phosphorylation of tyrosine
1349 and tyrosine 1356 of Met receptor β-chain is required for its biological activity in promoting
cell motility and invasion [162]. A direct interaction between the FERM domain of FAK and the
Met receptor, when Met is phosphorylated on tyrosine residues 1349 and 1356, has been reported.
This tyrosine phosphorylated peptide is proposed to directly bind several basic residues
(216KAKTLRK222) on the surface of the FERM domain of FAK [121]. As a consequence of this
interaction tyrosine phosphorylated Met relieves FERM-domain mediated autoinhibition of FAK
resulted in FAK activation. This interaction is important for promoting HGF induced cell invasion
[175].
The insulin like growth factor I receptor (IGF-IR) is a transmembrane receptor that initiates
a cascade of events that include mitogenic and antiapoptotic responses [176,177]. The relationship
between FAK and IGF1 signaling is complex and likely dependent upon cell context. Different
reports demonstrate that IGF1 induces FAK dephosphorylation through recruiting SHP2 or has no
effect upon FAK phosphorylation [178,179]. Others report FAK is important for IGF1 responses. FAK
and IGF-IR were found in the same complex in pancreatic adenocarcinoma cells [35]. This
interaction is direct and occurs between the catalytic domain of the IGF-1R and the F2 subdomain
of the FAK FERM domain [178]. Additional molecular details of the interaction and characterization
of the consequences of binding on the catalytic activity of IGF-1R and FAK have not been fully
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elucidated. Cell proliferation stimulated by IGF-1 is dependent on the presence of FAK. Dual
inhibition of both FAK and IGF-IR using dominant negative, siRNA and pharmacological
approaches decreased cell viability and increased apoptosis in cancer cells [35]
FERM Domain Binding Partners that Regulate the Cytoskeleton
With FAKs role in regulating cell motility, it is unsurprising that cytoskeletal regulators
would interact with FAK. Wiskott-Aldrich Syndrome (WAS) protein is encoded by WASL gene.
The WAS family of proteins share similar structure and are involved in signaling pathways that
regulate the actin cytoskeleton. N-WASP is one family member that is an effector of Cdc42
mediated actin cytoskeleton regulation in cells. FAK interacts with N-WASP and binding occurs
between the N-terminal domain of FAK (residues1-400) and N-WASP residues 148-273 [45]. This
interaction promotes phosphorylation of N-WASP at tyrosine 256 by FAK, and this phosphorylation
can regulate the subcellular location of N-WASP. FAK mediated N-WASP phosphorylation is
important in promoting cell migration [45]. Cell migration requires dynamic regulation of actin
filaments and focal adhesion complexes in lamellipodia.

In these structures, actin filament

polymerization is controlled by the Arp2/3 complex, which is regulated by Rac1 and Cdc42 through
WASP proteins. The FERM domain of FAK is also believed to interact with the Arp2/3 complex,
and thus may scaffold N-WASP and the Arp2/3 complex to control actin polymerization in
lamellipodia [46]. Interestingly, phosphorylation of tyrosine 397 of FAK impairs the interaction of
FAK with Arp 2 and Arp3, suggesting that FAK autophosphorylation triggers the release of the
Arp2/3 complex, which promotes initiation of nascent lamellipodia formation and cell spreading
[46,180].
FAK also interacts with C terminal region of myosin in cardiomyocytes. First identified by
a yeast two hybrid screen using the N terminal portion of FAK as bait, this interaction inhibits FAK
phosphorylation and activation [70]. Interestingly, FAK is localized to the sarcomeric A band in
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cardiomyocytes and pull down studies lead to the estimation that 40% of FAK is bound to myosin
in unstimulated cardiomyocytes [70]. In vivo studies showed that cardiac pressure overload
reduced this interaction and increased FAK phosphorylation. A later study used in silico modeling
and small angle x-ray scattering (SAXS) to futher identify the characteristics of this interaction [79].
The coiled coil of myosin rests in a cleft formed the the three subdomains of FERM opposite the
side that the linker binds to. Mutational studies further identified the sequence 158EIADQVDQE166
on the FERM domain as the sequence important for thins interaction [79]. Additionally, cyclic
stretch of cardiomycytes reduces this interaction and a FERM mimetic peptide can act as a decoy
for myosin, leading to the activation of FAK [79].
Other FERM Binding Partners
It was reported that the N-terminal domain of Ezrin interacts with amino acids 1-376 in the
FERM domain of FAK. This interaction may promote activity of FAK through increasing Tyr397
phosphorylation. Ezrin-dependent activation of FAK is not linked to cell-extracellular matrix
adhesion [181]. The molecular details of this interaction and significance of this mechanism of
regulation are currently unknown.
FAK also interacts with the PH domain of EtK directly through the FERM domain to
promote endothelial cell or epithelial cell migration. Activated FAK may play a critical role in
increasing the activity of EtK since the FAK Y397F mutant lacks the ability to activate EtK. The FAK
sequence mediating the interaction is unknown, but is presumably unique to FAK since Pyk2 fails
to bind Etk. The Y40 and E42 residues in the PH domain of EtK are critical for EtK activation by
FAK [182] Y40 is buried in the lipid binding pocket and E42 is on the surface of the PH domain in
the proximity of the lipid binding site (based upon the structure of the highly related Btk PH
domain). Under some scenarios, signaling via other tyrosine kinases might promote the association
of FAK and Etk. He et al. for example, demonstrate that the tyrosine kinase inhibitor, AG879 which
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is an inhibitor specific for ErbB2 and VEGF receptor FLK-1, inhibits the association of FAK and EtK
through activation of PAK1 [183]. While this is an intriguing mechanism of regulation, there are
several outstanding questions including the relationship between lipid binding and FERM domain
binding, and if lipid- and FERM-mediated activation occurs via similar mechanisms.
RIP is a family of proteins named receptor interacting proteins. They are serine/threonine
kinases that contain an N-terminal kinase domain and a C-terminal death domain. The death
domain of RIP1 interacts with a number of receptors that function in the induction of apoptosis.
RIP1 acts downstream of TNF-R1 to control NF-κB activation and thus plays a role in determining
whether cells survive or undergo apoptosis [184]. RIP interacts with the N-terminal domain of FAK
both in vivo and in vitro. RIP provides proapoptotic signals regardless of whether cells are
suspended or attached because RIP-/- cells were resistant to the effects FAK dephosphorylation and
degradation. Binding to FAK directly shifts the FAK-RIP balance towards resistance to apoptosis
and promotes survival in FAK overexpressed cancer cells. This is postulated as one mechanism used
by FAK to generate a strong survival signal in tumor cells [185].
Kadare et al found that the protein inhibitor of activated STAT1 (PIAS1) interacts with the
N-terminal domain of FAK in a yeast two-hybrid screen [186]. They identified residues 403-651 in
the PIAS1 C-terminal domain as the FAK binding site. This interaction would potentially induce
sumoylation of FAK at Lysine 152 and increase the phosphorylation level of FAK at tyrosine 397 in
cells. However, lysine 152 is buried in the structure of the FAK FERM domain, in the groove between
the F1 and F2 subdomains. In the autoinhibited FAK conformation, Lysine 152 lies between the
FERM and Kinase domains and is further inaccessible for sumoylation in this conformation.
Considerable structural rearrangement would be required to facilitate FAK sumoylation at this site.
But if sumoylation could occur, the SUMO moiety would certainly interfere with assembly of the
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autoinhibited conformation, consistent with the observed elevation in phosphorylation in the
sumoylated population of FAK.
Interactions with the Kinase Domain
As the kinase domain serves a catalytic function and most of the structural features are
required to carry out that function, it is unsurprising that there are few interacting proteins with
this domain. One protein does however interact with the catalytic domain in a very unique way.
FIP200 is the FAK family kinase-interacting protein of 200 kD [187]. It was originally identified in
a yeast two hybrid screen for Pyk2 interacting proteins. The C-terminal domain of FIP200 binds to
the catalytic domain of Pyk2 and impairs the activity of Pyk2 3-5 fold in vitro [187]. In transient
expression assays, FIP200 inhibited Pyk2 phosphorylation and the induction of apopotosis,
suggesting FIP200 can regulate biological responses to Pyk2. FIP200 also binds FAK. The Cterminal domain of FIP200 binds the N-terminal domain of FAK, while the middle and N-terminal
domains of FIP200 both bind the catalytic domain of FAK [188]. This interaction impairs kinase
activity in vitro. FIP200 complexes with FAK in cells in suspension and appears to dissociate upon
integrin dependent cell adhesion, particularly to fibronectin. Interestingly, FIP200 appears to
inhibit FAK-dependent phosphorylation of paxillin and Shc, but does not affect FAK-dependent
phosphorylation of p130cas and Grb7, in transiently transfected cells [188]. For a number of reasons,
FIP200 is an intriguing binding partner of FAK and Pyk2. The potential to tether the FERM and
kinase domains together is an exciting one. However, this interaction may be more specific to Pyk2,
as conditional knockout of FIP200 suggests that in vivo it is important for Pyk2 regulation but not
FAK regulation [189].
Proteins Interacting with Focal Adhesion Targeting Domain
The C-terminal FAT domain was originally defined as the sequence responsible for correct
subcellular localization of FAK to focal adhesions [139]. Its simple 4 alpha-helical bundle structure
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serves as a binding site for a number of proteins and is now established to engage multiple
transmembrane receptors and downstream substrates for phosphorylation.
The first FAT domain binding partner identified was the focal adhesion associated protein,
paxillin [190–192]. FAK binds to two peptide motifs (LD motifs) on paxillin and in turn has two
binding sites for paxillin in the FAT domain. Paxillin binding is one mechanism by which FAK is
localized to focal adhesions. Paxillin is also a substrate for FAK, and phosphorylation of paxillin on
Tyr118 recruits additional signaling molecules into complex to activate downstream signaling [193].
Paxillin also scaffolds signaling molecules in a phosphotyrosine-independent manner, including
PKL/Git2 (paxillin kinase linker) and β-pix (a guanine nucleotide exchange factor for Cdc42 and
scaffold for Rac and PAK). The FAK/paxillin complex also facilitates tyrosine phosphorylation of
PKL/Git2 and β-pix [194,195]. Tyrosine phosphorylation of β-pix impacts Rac recruitment and
tyrosine phosphorylation of PKL regulates cell polarization, lamellipodia stability and directional
persistence of migrating cells [195,195].
Growth factor receptor bound protein 2 (Grb2) contains an SH2 domain and a pair of SH3
domains [196]. The binding of Grb2 to FAK is dependent on phosphorylation of FAK at tyrosine
925, which creates a Grb2 SH2 domain binding site. This phosphorylation/binding site resides in
the first alpha helix of the FAT domain and conformational change of the FAT domain must precede
phosphorylation and Grb2 binding. The FAK/Grb2 interaction is induced by integrin receptors and
is coupled to activation of the Ras signaling pathway and downstream MAPK [196].
There is another group of proteins related to transcription signaling pathway which is
regulated by FAK activity. Over expression FAK causes activation of Stat1 which is one of the signal
transducer and activator of transcription (STAT) pathway proteins. STAT1 interacts with Cterminal of FAK directly [197]. The consequences of STAT1 binding are apparently a reduction in
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cell adhesion with an increase in cell motility through competition for focal adhesion localization
of FAK.
The endocytosis motif in the cytoplasmic domain of CD4 is similar to the LD motifs of
paxillin. The signature aspartic acid is not found in CD4, but the endocytosis motif is predicted to
form an amphipathic alpha helix similar to the LD motifs. A peptide mimicking the CD4 motif
(amino acids 405-417) binds the FAT domain of FAK with similar thermodynamic properties as the
paxillin LD4 motif. Both interactions show two binding sites on the FAT domain, are entropy
driven, and exhibit similar affinities [198]. Mutation of this sequence in the CD4 endocytosis motif
abolishes binding. The structure of this CD4 peptide in complex with the FAT domain of FAK has
been solved (PDB 3B71). The amphipathic alpha helix docks with two hydrophobic patches of the
FAT domain generally reminiscent of the interaction of paxillin LD motifs [198]. Interestingly, CD4
residues contacting the FAT domain are also critical for CD4 interactions with Lck, which binds
with significantly higher affinity. It is proposed that disruption of the CD4/Lck complex, e.g. by
cellular stimulation with the HIV gp120 protein, is required for the assembly of a CD4/FAK complex
[198].
Convergent lines of investigation led to the discovery that FAK plays a role in neurons to
regulate axonal outgrowth and guidance, and in oligodendrocytes to control branching. FAK
directly associates with the cytoplasmic domain of neogenin and DCC (deleted in colon cancer)
[199–201], which serve as receptors for netrin 1, an extracellular ligand controlling axonal
pathfinding and stimulating oligodendrocyte branching. The FAT domain of FAK mediates this
interaction with an LD-like motif in the C-terminal domain of neogenin/DCC [199–201].
Intriguingly, these receptors bind FAK but not Pyk2, but the basis of selective binding is unknown
[199]. This receptor/FAK interaction is essential for netrin 1 induced FAK tyrosine phosphorylation
and FAK is required for netrin 1 induced axonal outgrowth and guidance [199–201]. More recent
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investigation into netrin 1 growth cone guidance implicated the DCC/FAK interaction in a
mechanosensory role [202]. In this model, netrin activates DCC, which is bound to the FAK FAT
domain. The FERM domain is connected to the actin cytoskeleton through an interaction with an
adaptor, possibly Ezrin, allowing traction force to activate FAK through separation of the FERM
and kinase domains [202]. In addition to controlling neuronal outgrowth, netrin 1 also promotes
specific translation of the kappa opioid receptor in dorsal root ganglion neurons. FAK and the
associated adaptor protein, Grb7, have been identified as components of this signaling pathway
[203,204].
P190RhoGEF was identified as a FAK FAT domain binding partner in a yeast 2-hybrid screen,
and endogenous p190RhoGEF co-immunoprecipitates with endogenous FAK [44].

The

p190RhoGEF sequence extending from residue 1292 to 1301 is required for FAK binding, but the
extent of the binding site has not been defined [44]. This sequence is not similar to the LD motifs
of paxillin and thus binding apparently occurs via a unique mechanism, which remains to be
determined.

Cell adhesion to laminin or fibronectin induces tyrosine phosphorylation of

p190RhoGEF, which correlates with activation of Rho, and both of these signaling events are
dependent upon FAK [44,205]. This signaling pathway is proposed to regulate axonal branching in
Purkinje and hippocampal neurons by impairing branching and promoting axonal retraction via
activation of Rho [15].

Development of FAK Inhibitors
Based upon the expression of FAK in human tumors, the correlation of FAK expression or
amplification with disease outcome and the demonstration that FAK functions to promote
tumorigenesis and metastasis in animal models, there is considerable interest in FAK’s potential as
a therapeutic target. Several techniques have been used for the inhibition of FAK. Antisense
oligonucleotide and shRNA interference approaches have been used to inhibit FAK. However
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limitations in effective drug delivery systems for these reagents exclude them from use
therapeutically [206,207].

Several groups have reported the development of small molecule

inhibitors of FAK catalytic activity and others have suggested additional therapeutic strategies.
Currently the most promising FAK inhibition strategies are small molecule inhibitors .
The Genomics Institute of the Novartis research Foundation and the Novartis Institute for
BioMedical Research used rational drug design to produce Compound 1 [208]. This pyrrolo[2,3d]pyrimidine uses a five membered ring to bridge the four and five phosphates of the pyrimidine.
The results of molecular modeling and co-crystal structure analysis suggested that improvements
to specificity and inhibition could be made by adjusting the side groups [209]. The modifications
led to compound 32 which contains a 2-pyrimidine ring and extended carboxy group. This carboxy
group forms a salt bridge with Lys 454 and increases specificity to an IC50 of 4nM.
Another Novartis drug that is further along in characterization is TAE226. TAE is a bisanilino pyrimidine that interacts with the kinase hinge region [210]. It has an IC50 between 100 and
200 nM [211].

Two hydrogen bonds are formed between Cys 502 and the pyrimididine and 2-

methoxyaniline of TAE 226. Additional hydrophobic contacts between the pyrimidine and Ala 452
and Leu 553 as well as interactions between the 2-methoxyaniline and Ile 428 and Gly 505 hold the
inhibitor securely in place. The binding of the inhibitor in this way stabilizes the DFG motif in an
unusual helical conformation. This flexibility is due to a glycine directly before the DFG motif (PDB
2JKK). While this glycine is highly conserved in FAK it is rare in most other kinases [210]. However
this glycine is present in the IGF-IR which allows TAE226 to inhibit it as well. TAE226 increases
survival rates in rats with glioma and ovarian cancer xenografts, however because it also inhibits
IGF-IR it is unsuitable for trial in human subjects [211,212].
Another FAK kinase inhibitor is PND-1186 [213]. It has an IC of 1.5 nM for FAK and has the
unique characteristic of not having an inhibitory effect on FAK phosphorylation in adherent cells
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[213]. PND 1186 increases apoptosis in breast and ovarian carcinomas as well as reduces tumor
associated inflammation [213,214]. A twice daily oral dose of 150mg/kg prevented tumor growth
and metastasis to the lung in breast cancer xenografted mice [214].
Pfizer developed two separate FAK inhibitors, PF 573,228 and PF 562,271. Both compounds
were discovered through a combination of high throughput screening, structure based design, and
conventional medicinal chemistry and both are methane sulfonamide diaminopyrimidines
[215,216]. PF 573,228 has an IC50 of 4nM for FAK and 1μM for Pyk2 and is very specific to these two
kinases [216]. PF 573,228 inhibited cell spreading and migration as well as reduce cell growth. It
did not significantly reduce Tyr 397 phosphorylation. PF 562,271 has been characterized to a greater
extent than its counterpart and its crystal structure has been solved (PDB ID 3BZ3) [215]. It forms
three hydrogen bonds, two with Cys 502 and one with Arg 426. The sulfonamide group interacts
with the DFG motif, with the oxygen hydrogen binding to Asp 564. This moves Asp 564 upwards
and away from the ATP binding site, and creates the same helical DFG motif conformation seen
upon binding of TAE 226 [210,215]. PF 562,271 inhibits FAK phosphorylation in tumors as well as
increases apoptosis of tumor cells. Nude rats injected with MDA-MB-231 cells, mimicking a
secondary, post-metastatic tumor site, were given an oral dose of 5mg/kg [102]. This dosage
prevented the growth and spread of the bone metastases and reversed tumor induced bone loss
through inhibition of Pyk2. Similar results were seen with a combined dosage of PF 562,271 and the
antiangiogenic drug, sunitinib in a rat xenograft model with hepatocellular carcinoma cells [101].
Recently, Verastem acquired PF-04554878 and renamed it VS-6063 [217]. This company has worked
with the FAK inhibitor throughout clinical trials, including Phase I studies as a combination with
Paclitaxel ovarian cancer, and Phase II studies in non-small cell lung cancer and mesothelioma.
The newest FAK inhibitor is a small molecule inhibitor that also binds to the ATP binding
pocket in FAK developed by GlaxoSmithKline, called GSK2256098 [218]. It is very selective, with
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1000 fold greater selectivity for FAK over Pyk2 [219]. It inhibits both growth and survival in
pancreatic ductal adenocarcinoma cells, however the extent of the effect is variable across the 6
different PDAC cell lines tested [220]. Despite these variable results, GSK2256098 has passed Phase
I clinical trials in healthy individuals and patients with solid tumors [221]. Additionally, the results
of Phase I dose escalation study showed a promising effect in patients with solid tumors [219]. Three
more Phase I combination therapy studies with the drug and other cancer therapies are underway,
as well as a Phase I study in hypertensive patients [221]
A truly unique approach was taken in the development of Compound 14 [222]. A search of
the National Cancer Institute’s compound data base was combined with molecular modeling to
identify candidates. Compound 14, 1,2,4,5-benzenetetraamine tetrachloride, is very small and binds
directly Tyr 397. In vitro studies showed that it decreased phosphorylation of Tyr 397, cell adhesion,
cell viability and blocked tumor growth. However no specificity studies were completed, and
compound 14’s structure suggests many off target effects.
Since the FAT domain alone is also a potent dominant negative mutant [111], this domain is
considered a potentially significant therapeutic target to impair FAK signaling. A phage display
strategy was utilized to identify peptides that bind to the C-terminal domain of FAK. This resulted
in discovery of the AV3 peptide. The AV3 peptide can displace FAK from focal adhesions and impair
FAK function [223]. These studies were extended using an in silico screen for compounds that bind
to the FAT domain at the AV3 binding site. The compound, chlorpyramin hydrochloride [N-(4chlorobenzyl)-N',N'-dimethyl-N-pyridin- 2-ylethane-1,2-diamine], impaired FAK signaling in cells,
inhibited proliferation and induced apoptosis [224]. The crystal structure of this compound bound
to the FAT domain has been solved and deposited in the protein data bank (PDB ID 2RA7). The
compound docks to the alpha helix 1/4 side of the FAT domain, making extensive hydrophobic
contacts and H-bonding to Ser 939 (in helix 1) and His 1025 (in helix 4). The drug binding site
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partially overlaps the paxillin LD motif binding site, and His 1025 is one of the basic residues
flanking the hydrophobic patch on this side of the FAT domain. Thus this compound potentially
perturbs paxillin binding and might effectively displace FAK from focal adhesions, since the paxillin
binding site on the helix 1/4 surface of the FAT domain appears most important for localization
[149]. These hypotheses have yet to be addressed.

Phosphatidylinositol-(4,5)-bisphosphate Signaling in Focal Adhesions
The importance of PI(4,5)P 2 in focal adhesion signaling and cytoskeleton regulation has
been well established. As a precursor for the second messengers PI(3,4,5)P 3 inositol (3,4,5)trisphosphate, and diacylglycerol, its levels help to regulate cytoskeleton-membrane interaction
[225]. PIP5KIγ, a kinase capable of creating the PI(4,5)P 2 is recruited by the FERM domain of talin
to focal adhesions [226]. Once localized to adhesions, PIP5KIγ creates a localized increase of
PI(4,5)P 2 [227]. This FA specific pool of PI(4,5)P 2 is necessary for focal adhesion formation as well
as force generation.
integrins [228].

Localized PI(4,5)P 2 is necessary for the proper association of talin and

PI(4,5)P 2 also plays a role in the dimerization of vinculin and the vinculin

sequestration necessary for proper adhesion function [229,230]. PIP5KIγ is an upstream regulator
of FAK activity, which is unsurprising given the role of PI(4,5)P 2 binding in inducing conformational
change [122,167]. Another lipid kinase PIPKIβ, could also increase the local levels of PI(4,5)P2 ,
leading to its role in regulating focal adhesion disassembly through FAK activation and integrin
endocytosis [231]. Overall these studies show that the localized ebb and flow of PI(4,5)P 2 regulates
proteins necessary for the formation and disassembly of focal adhesions.
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Conclusion
The objective of this thesis was to elucidate more information regarding the mechanism of
activation for FAK. Previous research has highlighted the importance of the FERM domain,
particularly the F2 subdomain in regulation of FAK activation. Additionally, PI(4,5)P 2 and
phosphotyrosine binding are implicated in triggering a more active FAK molecule through the
release of the autoinhibited conformation. The following studies build on the previous literature
to better classify FAK activation in the context of disease, as well as the inter- and intramolecular
interactions that regulate the autoinhibited and open, active conformations.
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Figure 1: The structure of FAK. A) A cartoon representation of the domains of FAK organized
linearly. Tyrosine and serine phosphorylation sites, as well as PxxP binding motifs are highlighted.
The location of the KAKTLRK sequence is highlighted by the dark blue box. A) The crystal structure
of the FERM domain. F1 is shown in red, F2 in blue and F3 in green. B) The crystal structure of the
kinase domain. The ATP binding site holds a stick representation of an ATP analog. C) The crystal
structure of the FAT domain. The cooler colors start at the N terminus and the warmer colors end
at the C terminus. Tyrosine 925 is highlighted in yellow. (Adapted from Hall JE, Fu W, Schaller MD
(2011) Focal adhesion kinase: exploring Fak structure to gain insight into function. Int Rev Cell Mol
Biol 288: 185-225 with editor permission.)
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Chapter 2: Investigation of mutations found in patient samples and basic residues
on the FERM domain
Abstract
Focal Adhesion Kinase (FAK) is a non-receptor tyrosine kinase found in focal adhesions. It assists
in regulation of the assembly and disassembly of these adhesions during cell migration and plays a
role in integrin signaling and cell survival. FAK also integrates signals from several growth factor
receptors and has a scaffolding function that aids in integration of signaling pathways. It is
overexpressed in many cancers including colon cancer, ovarian cancer, and glioma. Additionally,
the FAK gene is amplified in breast cancer. Higher levels of FAK or increased catalytic activity can
be linked to poor prognosis and FAK is implicated in metastatic progression. FAK catalytic activity
is regulated through an autoinhibitory mechanism, in which the N-terminal FERM domain folds
over the active site of the kinase domain and is held in place by hydrophobic and charge
interactions. Previous studies have indicated a basic patch on the FERM domain in binding to small
ligands, such as PI(4,5)P 2 , and signaling for FAK activation through growth factor receptors such
as Met receptor.

Binding of these ligands to the FERM domain disrupts this interaction and

releases autoinhibition. The mechanism leading to this release of autoinhibition is not fully
understood. To this aim, two sets of mutations were assessed for their effect on release of
autoinhibition. The first set of mutants were identified in patient samples or tumor cell lines. These
mutations could give insight into a novel regulatory mechanism present in disease states. The
second were designed based on FAK structural data to provide insight into the physiological
method of activation. While it was hypothesized that mutating these residues would lead to a more
active FAK, results suggest that FAK activity is not increased by mutation in cancer but by
overexpression or upstream signals. Additionally, it was found that FERM domain residues may
contribute to the maintenance of the autoinhibited and open conformations.
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Introduction
Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase with an additional scaffolding
function. It plays an integral part in assembling signaling complexes in focal adhesions, which are
the sites of contact between the cell cytoskeleton and underlying extracellular matrix.

While

association with the matrix through integrins is a major mechanism of FAK regulation, FAK also
interacts with many growth factor receptors and participates in signaling downstream in these
pathways [1,2]. Because of its participation in focal adhesion signaling and growth factor signaling,
FAK serves three major roles in the cell: regulation of motility, promotion of cell survival, and
control of proliferation.
Given that aberrant growth, survival and motility are hallmarks of metastatic disease, it is
not surprising that FAK plays a significant role in the pathological state of cancer [3]. FAK
expression is increased in many cancers including melanoma, glioma, prostate, liver and ovarian
cancers [4,5]. Additionally, its gene is amplified in breast cancer [6]. Increased FAK expression or
activity has been linked to a higher rate of metastasis as well as poor prognosis in a number of
cancer types, including breast and ovarian cancers [4,7].

Determining the mechanisms of

regulation of FAK is important for understanding the progression of these diseases and the
development of new therapies [8].
FAK is a multidomain protein with three distinct structured domains. At the N terminal
end, FAK contains a band 4.1/Ezrin/Radixin/Moesin (FERM) domain [9]. Like most FERM domains
it is a three-lobed domain comprised of the subdomains F1, F2 and F3, however the FAK FERM
domain is structurally distinct from its family members. The FAK FERM domain has a different
arrangement of the subdomains and several areas where the exposed residues vary greatly from
other FERM domains giving FAK the potential for unique ligand interactions [10]. The FERM
domain is connected to the kinase domain by a short unstructured linker, which contains tyrosine
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397, the FAK autophosphorylation site [11]. C-terminal of the kinase domain there is a large
unstructured region that contains several proline rich sequences, SH3 domain binding sites, and
serine and tyrosine phosphorylation sites [12]. This region plays a large role in FAKs scaffolding
activity, with several phosphorylation sites and PxxP motifs. The C terminus is the Focal Adhesion
Targeting (FAT) domain. This antiparallel four helix bundle binds to paxillin through both
hydrophobic and charge-charge interactions and anchors FAK in the focal adhesions [13]. Recently
several crystal structures of domains of FAK have been solved, providing further insight into the
structural nuances of these three domains [10,13,14].
FAK activity is partially governed through autoinhibition.

In the autoinhibitory

conformation, the FERM domain folds over the kinase domain blocking the active site [14]. The
largest point of contact between the FERM and kinase domains is between the F2 subdomain of the
FERM domain and the large C-terminal lobe of the kinase domain. Here hydrophobic interactions
as well as charge-charge interactions hold the two domains together. Additionally the linker
between the two domains forms an anti-parallel β sheet with residues in the F1 subdomain. This
pulls the F1 subdomain close to the N-terminal lobe of the kinase domain [14].
Overall the mechanism for release of autoinhibition is not well understood. There is some
evidence that release of autoinhibition can be triggered by binding of an acidic ligand to a basic
patch on the surface of the F2 subdomain [15,16]. Phosphorylation of tyrosine 397 in the linker, and
possibly recruitment of Src into complex, could also break the β sheet interaction at the F1
subdomain. We set out to determine the mechanism of release of autoinhibition in order to better
understand the increase of FAK activity in cancer. The following studies used two different
strategies for identifying potential residues that could play a role in FAK activation. The first
approach was by identifying residues mutated in human tumor samples from the Catalogue of
Somatic Mutations in Cancer (COSMIC) database. The COSMIC database is maintained by the
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and
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(http://cancer.sanger.ac.uk/cosmic) [17].

of
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in

patient

samples

The second was a rational design approach that

identified residues in the FERM domain that interacted with the kinase domain. The residues R184,
K190 and K191 are in the alpha helix neighboring the

KAKTLRK221 sequence. The side chains of
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these residues formed a salt bridge with residues on the kinase domain. Interestingly these residues
and the corresponsing helix had different peptide backbone and side chain positions in the crystal
structures of FERM alone (PDB:2AL6) vs the FERM-Kinase complex (PDB:2J0J) [10,14] All of these
residues were basic with the potential to bind to an acidic ligand such as phosphotyrosine or
phospholipids. To neutralize the charge on these residues they were mutated to alanine.
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Materials and Methods
Molecular Biology
FAK mutants were created using a modified version of the Quickchange (Agilent)
mutagenesis protocol using CYFAK413 plasmid as a template. Primers for site-directed mutagenesis
were designed to substitute residues at the sites of interest. Sequence analysis verified the presence
of the intended mutations and that no unintended mutations were present. (ACGT inc).
Cell culture and reagents
HEK293 cells were maintained in Dulbecco’s Modified Eagle Medium containing 10% fetal
bovine serum and MDCK (ATCC, Manassas, VA) cells were maintained in Minimum Essential
medium with 10% fetal bovine serum. Cells were transfected with Lipofectamine 2000 or LTX (Life
Technologies Corp., Grand Island, NY) using manufacturer’s recommendations. Small molecule
inhibitor SU11274 was purchased from Tocris Biosciences (Minneapolis, MN). Recombinant human
Hepatocyte Growth Factor (Sigma, St. Louis, MO) was used at 20ng/ml. Antibodies used were antiFAK 4.47 monoclonal antibody (Millipore), anti-phospho pY397 FAK (Life Technologies), antiphosphotyrosine 4G10 (Upstate), anti-cMet C-28 (Santa Cruz), anti-GAPDH (Millipore), anti-Ecadherin (BD Biosciences)
Protein Analysis
Cells were lysed in ice-cold modiﬁed radioimmunoprecipitation assay (RIPA) buffer (50 mM
Tris-HCl [pH 7.3], 150 mM NaCl, 1% IGEPAL, 1% Nonidet P-40, 0.5% deoxycholate, 0.5% aprotinin,
1mM phenylmethylsulfonyl fluoride, 1.5mm vanadate). Lysates were clariﬁed, and protein
concentrations were determined using the bicinchoninic acid assay (Pierce). Lysates were boiled in
Laemmli sample buffer (60 mM Tris-Cl pH 6.8, 2% SDS, 10% glycerol, 5% β-mercaptoethanol, 0.01%
bromophenol blue) and 15 μg of total protein was analyzed by Western blotting. A FAK antibody
(4.47 ), a phosphotyrosine antibody (4G10) and FAK phosphospecific antibodies (PY577, PY397and
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PY861) were used as primary antibodies for Western blotting. Horseradish peroxidase (HRP)
conjugated anti-mouse and anti-rabbit secondary antibodies (Millipore) were used to detect
primary antibodies using Immobilon Western HRP chemiluminescence substrate (Millipore).
Quantification of blots was performed with ImageJ (http://rsb.info.nih.gov/nih-image). Developed
films were scanned as TIFF images in 8-bit grayscale format at 600 dpi. The lanes were defined
using the rectangular select tool and the Analyze → Gels → Select First Lane/Select Next Lane
function. Densitometry measurements were calculated using Analyze → Gels → Plot lanes. Band
peak was defined from background using the straight line tool then the area of the band peak was
calculated using the Wand tool. (Protocol can be found at http://rsb.info.nih.gov/nihimage/manual/tech.html#analyze.) Band intensities of the phosphotyrosine blots were divided by
the band intensities of the FAK blots and all wild type samples were normalized to one.
Kinase assay
HEK293 cells were transfected with FAK biosensors were lysed after 24 hours after
transfection with modified modiﬁed radioimmunoprecipitation assay (RIPA) buffer. Lysates were
clariﬁed, and protein concentrations were determined using the bicinchoninic acid assay (Pierce).
Lysates were diluted to yield a total protein concentration of 100µg/µl. 2µl of monoclonal antibody
BC4 for FAK was added to the lysates and incubated for 1 hour at 4°C. Protein A/G agarose beads
were added to the lysate and were incubated for 1 hour at 4°C with rocking. Beads were washed
twice with lysis buffer and then twice with kinase buffer (50mM tris-HCL pH7.4, 5mM MnCl 2 , 5mM
MgCl 2 ). Beads were resuspended in 25µl kinase buffer containing 2.5µg of a GST fusion protein
containing the FAK y397 peptide sequence and 25µM ATP. The reaction was incubated for 5
minutes at room temperature then stopped by adding 7.5µl of Laemmli sample buffer (60 mM TrisCl pH 6.8, 2% SDS, 10% glycerol, 5% β-mercaptoethanol, 0.01% bromophenol blue). The sample
was Western Blotted utilizing pY20 (Millipore) and 4.47.
66

Fluorometric measurements of FRET
For FRET measurements in the spectroflourometer, HEK 293 cells expressing FAK
constructs were washed with phosphate buffered saline (PBS) followed by detachment using PBS
containing 0.02% EDTA and transferred to a cuvette. The cell suspension was excited at 425nm
and emission scans (450nm-550nm) were acquired. The spectra of different samples in each
experiment were normalized to the CFP emission of the wild type biosensor spectrum.
For FRET measurements in the BioTek Synergy H4 Hybrid plate reader untransfected 293
cells and cells expressing FAK and/or cMet constructs were plated in a black clear bottomed 96well plate (BD Falcon). Full well emission scans were done with excitation and emission read pairs
of 425nm/470nm (CFP excitation/CFP emission), 470nm/530nm (YFP excitation/YFP emission),
and 425nm/530nm (CFP excitation/YFP emission; FRET signal). The cells were excited at 425nm
and emission scans (450nm-550nm) were acquired. The background fluorescence of untransfected
cells was subtracted and spectra of different samples in each experiment were normalized to the
CFP emission of a reference spectrum from a wild type biosensor. FRET ratios were calculated for
each well using both the well scan and emission scan data as an internal control.
Lipid Binding
Lipid binding was assessed by co-sedimentation with large, unilamellar vesicles (LUV). The
ability of the catalytic domain to bind PI(4,5)P 2 was analyzed using lipid vesicles containing
50%PC/40%PE/10% PI(4,5)P 2 (experimental) or 60%PC/40%PE (control). Vesicles were prepared
by mixing chloroform dissolved phospholipids (Echelon) in appropriate ratios. The mixture was
dried using a speed vacuum for 15 minutes. The dried lipid cake was suspended into a lipid binding
buffer (20 mM HEPES [pH 7.5], 2 mM dithiothreitol, 250 mM NaCl) to a final concentration of 2.5
µg/ul [18]. The lipid suspension containing large multilamellar vesicles (LMV) was passed eleven
times through a 100 nm filter using an Avanti mini-extruder set to ensure a homogenous suspension
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of LUVs. Four micrograms of glutathione S-transferase (GST) fusion protein was incubated with
250 µg of lipid vesicles on ice for 1h. The mixtures were centrifuged at 100,000 x g for 1h at 4 C°. The
supernatants were collected, mixed with Laemmli sample buffer (60 mM Tris-Cl pH 6.8, 2% S.D.S,
10% glycerol, 5% β-mercaptoethanol, 0.01% bromophenol blue) and boiled. The pellets were
resuspended in Laemmli sample buffer and boiled. The samples were analyzed by S.D.Spolyacrylamide gel electrophoresis (PAGE) and Coomassie blue staining. Quantification of gels
was performed with ImageJ (http://rsb.info.nih.gov/nih-image). Images of gels were converted to
TIFF images in 8-bit grayscale format at 600 dpi. The lanes were defined using the rectangular select
tool and the Analyze → Gels → Select First Lane/Select Next Lane function. Densitometry
measurements were calculated using Analyze → Gels → Plot lanes. Band peak was defined from
background using the straight line tool, then the area of the band peak was calculated using the
Wand

tool.

(Protocol

can

be

found

at

http://rsb.info.nih.gov/nih-

image/manual/tech.html#analyze.) Band intensities of the supernatant and pellet lanes were
divided by the sum of the band intensities of the supernatant and pellet.
FRET measurements in response to HGF stimulation
MDCK cells transfected with FAK biosensor constructs were plated onto collagen coated
(50ug/ml) glass bottom microwell dishes (MatTek Corp, Ashland, MA). Dishes were placed in a
CO 2 and temperature controlled environmental chamber mounted onto a Nikon Swept Field
confocal. Cells expressing biosensors were visualized with a Nikon 40x oil objective and imaged
using Nikon Elements FRET module with exposure times of 200msec for YFP, and 800msec for CFP
and FRET channels (Hahn ref). Background subtraction was performed followed by generation of
a ratio image of CFP divided by FRET channels. Cells were outlined and intensity averages of each
channel along with FRET ratios were recorded using the Nikon Elements Analysis software.
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Results
COSMIC Mutations Have No Effect on FAK Activation
Several FAK mutations are present the in COSMIC database.

Although the overall

mutation rate of FAK in cancer is extremely low (1%), several of the mutations occurred at intriguing
sites within the FAK structure. Further analysis of these mutants could provide insight into FAK
activation. The first mutation, F147C, was identified in a non-small cell lung cancer patient. It is
located in the α2 helix of the F2 FERM subdomain and makes contacts with side chains of residues
in the α1 and α2’ 310 helices. The F2 subdomain is the largest point of contact with the kinase
domain in the autoinhibitory conformation, making a structural disruption of this subdomain likely
to cause a disruption in autoinhibition. The second mutation, D402V, was also found in a nonsmall cell lung cancer patient.

This residue is in the linker very near the Y397 and Y407

phosphorylation sites. The mutation also removes a charged side group from the linker. This could
disrupt FAK autophosphorylation at Y397 and Y407. The third mutation, A590V, was identified in
human glioma patient. It is located in the kinase domain shortly past where the activation loop
rejoins the C lobe. A disruption here could cause a change in activation loop conformation,
inhibiting autoinhibition (Figure 1). Three different FAK mutants were created based on these
mutations.
Previously, a FRET based biosensor of FAK was developed, CYFAK413 [19]. This construct
consists of a CFP at the N terminus of FAK and YFP inserted in the linker near the kinase domain.
When FAK is in the autoinhibited conformation, the acceptor and donor fluorophores are in close
proximity and the FRET signal is high. Release of the autoinhibitory conformation causes a
reduction in FRET. Using a modified Agilent Quickchange protocol the CYFAK413 biosensor was
mutated to create three constructs containing residue substitutions mimicking the mutations in
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the COSMIC database. These mutations were analyzed to determine if they resulted in altered FAK
conformation and activation.
To determine levels of FAK protein produced and phosphorylation, populations of HEK293s
expressing each construct were lysed and lysates were analyzed by Western blotting (Figure 2 A &
B). A mutant of FAK, Y180A/M183A, that is incapable of maintaining the autoinhibited
conformation was used as a control in all experiments. FAK phosphorylation at Tyr397 was not
affected by the F147C and D407V mutants. FAK expression levels and Tyr397 phosphorylation were
significantly decreased in the A590V mutant. To confirm that the changes in phosphorylation were
due to FAK autophosphorylation activity and not the disruption of an upstream activating signal,
in vitro kinase assays were performed. FAK was immunoprecipitated from transiently transfected
HEK293 cells and incubated with a fusion protein substrate which mimics the Y397
phosphorylation site for 5 minutes. The reaction was then blotted for FAK and phosphotyrosine.
The catalytic activity of the F147C and D407V mutants were similar to that of the wild type protein
(Figure 2 C & D). There was no detectable catalytic activity in the A590V mutant. Thus none of
the mutants lead to a more active kinase, with two having activity comparable to wild type and one
being catalytically dead.
Despite the lack of change in kinase activity in an in vitro kinase assay these areas may be
important for the conformational change needed to create an active kinase in vivo. To test whether
these residues were important for conformational change, HEK293 cells expressing the mutated
biosensor constructs were trypsinized and suspended in PBS for analysis in a spectrofluorometer.
Two of the three mutations, F147C and D407V, caused no conformational change indicating no
effect on the maintenance or release of the autoinhibitory conformation. Nor did they result in
increased tyrosine phosphorylation when expressed transiently in cells, confirming the results from
the in vitro kinase assay. The third, A590V mutant, exhibited an aberrant emission profile (Figure
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3 A & B). The expression level of the mutant was low and exhibited a phosphorylation defect when
the biosensor was transfected into HEK293 cells. This mutation is in the highly conserved “APE”
sequence in the C-lobe of the kinase domain. As such, this sequence may be essential for the
stability of the kinase domain. These results indicate that while FAK is a major player in cancer,
these three naturally occurring mutations are not the mechanism by which its activity is increased.
This underscores the importance of understanding the molecular structure and signaling pathways
that regulate FAK autoinhibition.
Rational design of FERM domain mutations based on crystal structures
In order to identify residues that may be important for the physiological regulation of FAK
activity, the available crystal structures of FAK were analyzed. Currently, there are two crystal
structures available for the FAK FERM domain, the FERM domain alone (PDB: 2AL6) and the FERM
domain in complex with the kinase domain (PDB: 2J0K) [10,14]. FERM F2 subdomain of FAK
contains a basic patch that is necessary for FAK activation [13]. This basic patch consists of two
ridges (Figure 4). The first ridge, 216KAKTLRK221, is on the apex of the F2 subdomain plays a role in
FAK activation and some ligand binding [13].

The second, the RKK ridge is composed of

R184/K190/K191, runs along the interface between the FERM domain and the Kinase domain.
Examination of the two crystal structures for differences in FERM domain residues identified the
RKK ridge as potential regulators of autoinhibition. In the FERM-catalytic domain crystal structure
the side chains of these residues face the catalytic domain and the side chains interact with the side
chains of residues on the kinase domain to form a salt bridge. Thus they could potentially be
involved in inhibition through maintaining a charge-charge interaction with the kinase domain. In
the structure containing FERM alone these side chains point away from the space that would be
occupied by the kinase domain. This suggests the RKK ridge could play a role in activation through
ligand binding to release the kinase domain. These candidates are supported by studies prior to the
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crystallizations which mutated K190 and K191 and then observed a reduction in FERM domain
binding to full length FAK [15]. However, the impact was largely unremarked upon because it was
an intermediate effect overshadowed by the large change in FAK activity shown by mutating
the

KAKTLRK221 sequence [15]. Based on both the location of these residues and their altered
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positions in the crystal structures, it was hypothesized that these are key regulatory residues for
autoinhibition (Figure 4B).
Impact of FERM Domain Residues on Basal Conformation
To determine the impact of R184 and K190 on activation of FAK, these residues were
mutated to alanine in the FRET based CYFAK413 biosensor [13]. HEK293 cells transfected with the
wild type or mutated CYFAK413 biosensor were held in suspension in a cuvette and FRET was
measured utilizing a spectrofluorometer. FAK should be less active in nonadherent cells so this is
an ideal way to observe activating mutations. When transfected into HEK293 cells, the mutated
version of the biosensor had lower levels of FRET (Figure 5A) indicating the mutated FAK molecule
has a more open conformation. This suggests these residues have a role in maintaining the
autoinhibited conformation. This difference, while consistent, was not statistically significant
(Figure 5B).
To assess the role of these residues in FAK in a more physiologically relevant context,
HEK293 cells transfected with the CYFAK413 biosensor were attached to tissue culture treated
plastic 96-well plates in serum containing media. This allowed CFP, YFP, and FRET channel
emissions to be observed using a Synergy H4 plate reader. Adhesion is important for the assessment
of FAK conformation, as outside of focal adhesions FAK should always be inhibited. In adherent
cells the R184A mutant had a FRET signal indistinguishable from wild type. While the K190A
mutant had a trend towards a lower level of FRET these results were not statistically different from

72

wild type (Figure 5C). These results suggest the residues R184 and K190 might play a role in
maintaining the autoinhibitory, closed conformation of FAK.
To evaluate the role of the entire ridge a triple-mutant was created. The new construct
R184A/K190A/K191A, was tested in adherent cells. The R184A/K190A/K191A mutant consistently had
a lower FRET profile than wild type. However, again this was not statistically significant (Figure 6).
These results suggest these residues have a stabilizing effect on the autoinhibitory conformation,
but are not vital for maintaining that conformation as other residues can compensate.
Impact of FERM domain on lipid binding
As the 216KAKTLRK221 sequence binds acidic ligands such as PI(4,5)P 2 and phosphotyrosine,
it was hypothesized that the RKK ridge may also be required for ligand binding. To assess FERM
domain binding to phospholipids, large unilamellar lipid vesicles composed of 60%
phosphatidylcholine (PC) and 40% phosphatidylethanolamine (PE) were prepared as control
vesicles and experimental vesicles containing 10% PI(4,5)P 2 /50%PC/40%PE were made. GST-FERM
domain fusion proteins were incubated with lipid vesicles for 1 hour on ice prior to vesicle
sedimentation at 100,000 x g for 1 hour at 4oC. The amounts of fusion protein partitioning into the
pellet (lipid bound) and supernatant (free) were determined by analyzing the two fractions by
S.D.S-PAGE and Coomassie blue staining. In the absence of lipid vesicles, each protein was
exclusively found in the supernatant (Figure 7). In the presence of PC/PE vesicles, a fraction of the
GST-FERM domain fusion protein co-sedimented with the vesicles (10.1%). A larger fraction of the
GST-FERM domain fusion protein (47.5%) co-sedimented with PI(4,5)P 2 containing vesicles
(Figure 7A). To determine the role of the FERM domain basic residues in vesicle binding, two
mutants

KAKTLRK222 and R184A/K190A/K191A were analyzed for co-sedimentation with lipid
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vesicles. The 216KAKTLRK222 mutant FERM domain fusion protein was found in the supernatant in
the absence of lipid vesicles. In the presence of PC/PE lipid vesicles, a fraction of the
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216KAKTLRK222 fusion protein co-sedimented with the vesicles (10.8%). A similar fraction of the
mutant fusion protein co-sedimented with PI(4,5)P 2 -containing vesicles (15.6%) (Figure 7B). The
R184A/K190A/K191A mutant FERM domain fusion protein was found in the supernatant in the
absence of lipid vesicles. In the presence of PC/PE lipid vesicles, a fraction of the
R184A/K190A/K191A fusion protein co-sedimented with the vesicles (21.5%). A larger fraction of the
mutant fusion protein co-sedimented with PI(4,5)P 2 -containing vesicles (37.0%) (Figure 7C).These
findings demonstrate that the FAK FERM domain exhibits some binding to PC/PE vesicles, that
binding is increased in the presence of PI(4,5)P 2 . Additionally they confirm that the 216KAKTLRK222
ridge is the main binding site on the FERM domain. However mutation of the R184, K190, and K191
reduces the amount of PI(4,5)P 2 binding from 47.5% to 37.0% indicating that this may be a
secondary phospholipid binding site.
Development of an Assay to Assess FAK Response to Activating Stimuli
Up until this point, FRET experiments were performed in unstimulated cells. For evaluation
of the role of the basic ridge residues in response to activating stimuli, a new assay needed to be
developed. This assay needed to enable the observation of relatively quick changes in FAK
activation. While adhesion leads to a more active FAK population it is a slow process and poses
imaging challenges as cells change shape over time. Several stimuli have been shown to activate
FAK. Lysophosphatidic acid (LPA) stimulation and treatment with platelet derived growth factor
were utilized previously to activate FAK [19]. Hepatocyte Growth Factor (HGF) or “scatter factor”
binds to and activates the met receptor which in turn binds to and activates FAK [20]. This
activation triggers cell motility and epithelial cells will take on a more mesenchymal phenotype [21].
The molecular mechanisms regulating FAK in response to HGF are better established than other
stimuli.

For activation by HGF the

KAKTLRK221 sequence is needed. This makes it a better

216

stimulus for experimentation as the KAKTLRK mutant can be utilized as a control. It is expected,
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but not proven, that HGF stimulation leads to FAK conformation change, so experiments
establishing this were performed. The CYFAK413 biosensor was co-transfected with the Met
receptor or tpr-met, an oncogenic fusion protein that leads to a constitutively active met kinase
domain, into HeLa [22]. This co-expression lead to a decrease in FRET and a more active FAK
population in suspended cells (Figure 7A). Subsequently, treatment of these cells with a met
receptor inhibitor lead to a return to basal levels of FAK activation and FRET; confirming the FRET
change was a direct result of met receptor activation (Figure 10B).
As they express the Met receptor and respond to HGF, as evidenced by morphology change
and cell scattering Madin Darby Canine Kidney (MDCK) cells were transfected with the FAK
biosensor. Using an epifluorescent microscope fitted with a live cell chamber, FRET signal was
monitored to establish a baseline FRET ratio. FRET Ratio was defined as the emission in the CFP
channel divided by the emission in the YFP channel when excited at the CFP excitation wavelength.
Once a baseline was established cells were treated with 20ng/ul HGF and FRET measurements were
acquired at 1 min intervals over a period of an hour. The FRET ratio at each of these time points is
then compared to the baseline ratio established at the beginning of the experiment. The FRET ratio
of wild type biosensor in untreated cells stayed constant over an hour of imaging. In cells treated
with HGF, the FRET ratio increased over the course of imaging (Figure 7C). As this ratio is inverted
an increase is indicative of decreasing YFP emission at CFP excitation, indicating a decrease in FRET
and thus a release of autoinhibition in response to HGF stimulation.
Impact of FERM Domain Residues on Response to Activating Stimuli
The HGF assay can assess activation in response to ligand. The mutation of the RKK ridge
residues may lead to destabilization of the autoinhibited conformation and sensitize activation.
Additionally, If these residues are needed to bind ligand, this assay can detect an impairment in
response to activating signals. Utilizing the HGF assay, MDCK cells transfected with the wild type
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and mutated biosensors were monitored for FRET efficiency following stimulation. There was no
difference in the rate of change in FRET in response to HGF stimulation over time between wild
type biosensor and R184A/K190A mutant (Figure 10A). However the K190A/K191A mutant appeared
sensitized to upstream signals with a greater change in FRET over time. Interestingly, the response
from both of these mutants was much more varied than the wild type biosensor, as illustrated by
the error bars (Figure 10A). To better assess the effect of this ridge the R184A/K190A/K191A triple
mutant response to HGF stimulation was evaluated. While the mutation of this entire ridge did
not yield a net change in FRET ratios statistically different from that of wild type, again the variance
of response was much higher as illustrated by the error bars (Figure 10B). This indicates that while
the net effect of mutating these residues is small, they may play dual roles in ligand binding and
autoinhibitory conformation stabilization, which cancel their effects out.
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Discussion
While the chromosomal region that contains the FAK gene (8q24.3) is susceptible to
carcinogenic mutations, mutation of FAK in patient samples is rare [23]. In cancer over expression
of the fak gene is the mechanism for altered FAK activity, and this overexpression of FAK is linked
to poor outcomes especially in ovarian and breast carcinomas [24–26]. Our hypothesis was that the
mutations identified in the COSMIC database contained in the FERM and catalytic domains of FAK,
would result in activation of FAK. However, as our data shows, the F147C and D402V mutations do
not affect the autoinhibition of FAK. The A590V mutation created a nonfunctioning version of the
biosensor so its effect on autoinhibition could not be properly assessed. It did however result in a
kinase dead mutant. A590 is in the highly conserved APE sequence that is considered the “end” of
the activation loop, so might cause a change in activation loop structure upon phosphorylation.
The FAK effect in the A590V mutant is potentially due to its scaffolding capabilities. Thus the FAK
effect in these cancers must be a result of different mechanisms. This evidence emphasizes the
importance of understanding the signaling pathways that activate FAK and the mechanism for FAK
overexpression in cancer.
The second set of residues investigated in this study were identified through investigation
of the crystal structures of FAK. These residues form one of two basic ridges along the F2
subdomain of FAK. The first ridge, KAKTLRK, binds to PIP2 and is necessary for proper FAK
activation [15,16]. The second ridge formed, by R184, K190, and K191, is part of the interface between
the FERM and kinase domains in the autoinhibited structure [10]. They also border the pocket that
holds F596 in the autoinhibited conformation [14,16]. Besides the location of these residues the
positions of their side chains in crystal structures were intriguing. In the crystal structure of the
FERM domain alone the side chains are pointed up and away from the space that would be occupied
by the catalytic domain [10]. The crystal structure containing both the FERM and kinase domains,
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the side chains of these residues are facing the catalytic domain [14]. This change in side chain
position suggested a switch in positioning between the autoinhibited and active conformation.
Interestingly, a K190AK191A mutant was investigated during the characterization of KAKTLRK [15].
While not thoroughly investigated, a GST-KK construct had reduced pull down of full length FAK
suggesting a reduction in the maintenance of the autoinhibited conformation [15].
Mutation of these basic residues to alanine had no effect on FAK catalytic activity but it did
have some effect in the FRET biosensor signal. The decrease in FRET signal, while not significant
was consistent. These results suggest that while the basic side chains are not essential for the
autoinhibited conformation they may be important for stabilization. The lack of a difference in
FRET change in response to upstream activating signals suggests that these residues are not
important for binding a negative ligand like KAKTLRK. However, lipid sedimentation studies with
the RKK mutant lead to a 10% decrease in lipid binding. This affinity may be masked as these
residues are partially buried in the autoinhibited conformation. Together these experiments expand
the picture of FAK autoinhibition, in which the side chains of the FERM domain help to stabilize
the conformation held together by the lock and key created by Y180, M183, and F596.
Mutation of these basic residues to alanine had no effect on FAK catalytic activity but it did have
some effect in the FRET biosensor signal. The decrease in FRET signal, while not significant was
consistent.

These results suggest that while the basic side chains are not essential for the

autoinhibited conformation they are important for stabilization. The lack of a difference in FRET
change in response to upstream activating signals suggests that these residues are not important
for binding a negative ligand like KAKTLRK. However, lipid sedimentation studies with the RKK
mutant lead to a 10% decrease in lipid binding. This affinity may be masked in full length FAK as
these residues are partially buried in the autoinhibited conformation. Together these experiments
expand the picture of FAK autoinhibition, in which the side chains of the FERM domain help to
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stabilize the conformation held together by the lock and key created by Y180, M183, and F596. The
original hypothesis posed was that the RKK ridge shifts conformation during ligand binding to
release the catalytic domain. These studies suggest that autoinhibition is released through another
mechanism. Based on the current literature, the most plausible hypotheses are a mechanosensory
mechanism in which cytoskeletal force pulls the two domains apart, or binding of ligands to a
second site on FAK to prompt release of the autoinhibited conformation.
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Figure Legends
Figure 1: The FERM-kinase autoinhibited structure. The FERM domain is shown in light magenta and
the kinase domain is shown in light cyan. The linker is shown in grey. Side chains of residues that
were mutated are shown as sticks.
Figure 2: Biochemical characterization of COSMIC mutants A) Western blot showing FAK expression
levels. B) Western blot showing the pY397 levels from cells transfected with wild type or mutated
FAK. (n = 3) C) FAK western blot showing the amount of FAK contained in an in vitro kinase assay.
D) Western blot showing the amount of phosphorylated substrate at the end of an in vitro kinase
assay. (n = 3)
Figure 3: Conformational characterization of COSMIC mutants A) FRET ratios for wild type and
mutated biosensors (n = 12). B) A representative emission scan of wild type and mutated biosensors.
Figure 4: Structural features of interest in the FERM domain A) A surface view of the FERM-kinase
domain autoinhibited structure. The FERM domain is shown in light magenta, the catalytic domain
is shown in light cyan. The KAKTLRK ridge is shown in purple and the RKK ridge is shown in
magenta. B) A ribbon diagram of the FERM-catalytic domain crystal structure. The side chains of
R184, K190, and K191 are shown as sticks. C) A ribbon diagram of the FERM domain crystal
structure. The side chains of R184, K190, and K191 are shown as sticks.
Figure 5: Conformational characterization of R184A and K190A in suspended cells A) A representative
emission scan of wild type and mutated biosensors. B) FRET Ratios of wild type and mutated
biosensors in suspended cells (n = 12). C) FRET ratios of wild type and mutated biosensors in
adherent cells (n = 40).
Figure 6: Conformational characterization of R184A/K190A/K191A in adherent cells A) A
representative emission scan of wild type and mutated biosensors. B) FRET Ratios of wild type and
mutated biosensors in adherent cells (n = 10).
83

Figure 7: R184A/K190A/K191A reduces FERM lipid binding. GST fusion proteins were incubated in
buffer alone or with large unilamellar vesicles comprised of 60%PC/40%PE (PC/PE) or
50%PC/40%PE/10% PI(4,5)P 2 (PI(4,5)P 2 ). The samples were sedimented at 100,000 x g and the
supernatant (S) and pellet (P) fractions analyzed by S.D.S-PAGE and Coomassie blue staining (Top
Panel A, B, and C). The results of quantification of multiple experiments (n=3) is shown in the
bottom panels. The partitioning of the wild type FERM domain of FAK (panel A), the KAKTLRK
mutant FERM domain (Panel B) and the RKK mutant FERM domain (panel C) between supernatant
(S) and pellet (P) fractions is shown. Gels were analyzed using ImageJ and the fraction of each
protein in the supernatant and pellet (+/- S.D.) was plotted.
Figure 8: Development of an assay for FAK response to upstream signals A) A representative emission
scan of cells transfected with either biosensor (413) alone or with wild type Met or TPR-Met. B) A
representative emission scan of cells transfected with either biosensor (413) alone or with wild type
Met and treated with a met receptor inhibitor. C) Comparison of FRET ratio over time between
untreated cells and cells treated with 20ng/ul of HGF (n=6).
Figure 9: R184A/K190A/K191A does not affect FAK response to activating signals. A) The change in
FRET ratios over time for wild type and mutant biosensor transfected MDCKs treated with HGF (n
= 28-32 cells each over 4 experiments). B) The change in FRET ratios over time for wild type and
mutant biosensor transfected MDCKs treated with HGF (n = 40 - 58 cells each over 6 experiments).
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Abstract
Focal adhesion kinase is an essential nonreceptor tyrosine kinase that plays an important role in
development, in homeostasis and in the progression of human disease. Multiple stimuli activate
FAK, which requires a change in structure from an autoinhibited to activated conformation. In the
autoinhibited conformation the FERM domain associates with the catalytic domain of FAK and
PI(4,5)P 2 binding to the FERM domain plays a role in the release of autoinhibition, activating the
enzyme. An in silico model of FAK/PI(4,5)P 2 interaction suggests that residues on the catalytic
domain interact with PI(4,5)P 2 , in addition to the known FERM domain PI(4,5)P 2 binding site. This
study was undertaken to test the significance of this in silico observation. Mutations designed to
disrupt the putative PI(4,5)P 2 binding site were engineered into FAK. These mutants exhibited
defects in phosphorylation and failed to completely rescue the phenotype associated with fak

-/-

phenotype fibroblasts demonstrating the importance of these residues in FAK function. The
catalytic domain of FAK exhibited PI(4,5)P 2 binding in vitro and binding activity was lost upon
mutation of putative PI(4,5)P 2 binding site basic residues. However, binding was not selective for
PI(4,5)P 2 , and the catalytic domain bound to several phosphatidylinositol phosphorylation variants.
The mutant exhibiting the most severe biological defect was defective for phosphatidylinositol
phosphate binding, supporting the model that catalytic domain phospholipid binding is important
for biochemical and biological function.
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Introduction

Focal adhesion kinase (FAK) is an essential non-receptor tyrosine kinase since fak-/- mice

exhibit embryonic lethality. FAK is broadly expressed in different cell types and loss of FAK
expression or function results in multiple embryonic defects including deficits in angiogenesis,
formation of the neural tube and development of a multi-chambered heart [1–3]. Homeostasis in
some adult tissues is also dependent upon FAK, as demonstrated in conditional FAK knockout
mouse models. For example, in keratinocytes FAK is necessary for maintenance of an epidermis of
normal thickness and for sebaceous gland function, and in intestinal epithelial cells, FAK is required
for efficient mucosal wound healing [4,5]. FAK also plays a role in the development of pathologies
associated with several human diseases. The most extensive evidence has implicated FAK in the
development and progression of a number of cancers and significant efforts to therapeutically
target FAK with small ATP analog inhibitors have been made [6,7]. FAK has also been implicated
in atherosclerosis, and the tissue remodeling that occurs during cardiac hypertrophy [8–10]. At the
cellular level, FAK regulates cell proliferation, cell survival, and cell migration, and control of these
cellular events underpins the biological functions of FAK in development, homeostasis, and disease
[11–13].
Given its broad distribution of expression across tissues and role in controlling multiple
cellular and biological functions, it is not surprising that a wide range of stimuli can activate FAK
signaling. Integrin-dependent cell adhesion to extracellular matrix proteins is a major activating
signal and soluble ligands for receptor tyrosine kinases and G protein coupled receptors can trigger
FAK activation [14]. These diverse stimuli initiate catalytic activation of FAK and
autophosphorylation, which creates a binding site for Src, another nonreceptor tyrosine kinase,
which in turn phosphorylates FAK at additional sites [15–17]. Tyrosine phosphorylation of FAK
stimulates maximal catalytic activity in addition to regulating FAK’s ability to serve as a scaffold to
assemble a complex of signaling molecules to transduce downstream signals [18].
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The critical event in FAK activation is a conformation change from an autoinhibited to an
activated state. In the autoinhibited conformation, the FAK band 4.1, Ezrin, Radixin, Moesin
(FERM) domain binds to the catalytic domain to occlude the active site and substrate binding
site[19]. There are two contact sites in this conformation, one between the C-terminal lobe of the
kinase domain and the F2 lobe of the FERM domain and the second between the N-terminal lobe
of the kinase domain, the linker between the FERM and kinase domains, and the F1 lobe of the
FERM domain (Figure 1). Activating stimuli are proposed to modify the FERM domain or generate
a FERM domain binding ligand that reduces the affinity of the FERM domain for the catalytic
domain relieving the inhibitory interaction and/or stabilizing the active conformation.
Phosphorylation of FAK at tyrosine 194 by the Met receptor tyrosine kinase is proposed to relieve
autoinhibition in response to hepatocyte growth factor stimulation, and Src-dependent
phosphorylation of the activation loop of FAK is believed to sterically block FERM domain binding
to the catalytic domain, thus stabilizing the active conformation [19,20]. A change in intracellular
pH also modulates FAK activity through a mechanism of protonation/deprotonation of histidine
75, which resides in the FERM domain and is proposed to alter the stability of the autoinhibited
conformation [21]. A FERM domain basic sequence in the F2 lobe lies near the interface with the
kinase domain and is required for FAK activation [22]. This sequence serves as a binding site for
two different ligands, a tyrosine phosphorylated peptide from the Met receptor and PI(4,5)P 2
[23,24]. Binding of these ligands to the basic sequence in the FERM domain is envisioned to relieve
autoinhibition.
The role of PI(4,5)P 2 binding in FAK activation has been experimentally addressed using
biochemical and computational approaches. FAK binding to PI(4,5)P 2 is cooperative and induces
FAK clustering in vitro [25]. The FERM domain mediates FAK dimerization, which is required for
biochemical and biological function in vivo [26]. However, dimerization occurs in vitro in the
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absence of PI(4,5)P 2 and thus the role of this interaction in PI(4,5)P 2 -induced clustering has not
been elucidated. Molecular dynamics simulations have been performed to gain insight into the
molecular mechanism of FAK activation by PI(4,5)P 2 . Allosteric connectivity is observed between
alpha helix C and alpha helix G, which reside in the N-terminal and C-terminal lobes of the catalytic
domain respectively. Alpha helix C contacts the linker, which contacts the F1 lobe of the FERM
domain, and alpha helix G directly contacts the F2 lobe of the FERM domain in the autoinhibited
state [19,25]. PI(4,5)P 2 docking induces local changes in the F2 lobe of the FERM domain, and also
induces long range changes between the N-terminal lobe of the kinase domain and the F1 lobe of
the FERM domain [25,27]. In these simulations, PI(4,5)P 2 binding induced small changes in the
conformation of the FERM/kinase domain and did not cause dissociation of the two domains
[25,27,28]. Additional events may therefore contribute to the conversion of the autoinhibited to
fully activated state. Molecular dynamics simulations have demonstrated that PI(4,5)P 2 sufficiently
tethers the FERM domain to allow mechanical separation of the FERM and catalytic domains when
forces are applied to the C-terminus of the catalytic domain [29]. This is an interesting model given
FAK’s role in sensing mechanical stiffness of the extracellular matrix and the requirement of an
intact actin cytoskeleton for activation [30–32]. Interestingly, one of the molecular dynamics
simulation studies suggested a novel interaction between the catalytic domain and PI(4,5)P 2 [28].
In addition to the interaction of the F2 lobe basic sequence with PI(4,5)P 2 , basic residues in the
catalytic domain also docked with PI(4,5)P 2 in these simulations. Of interest were a number of basic
residues on the side of the large lobe of the catalytic domain as a rotation of the catalytic domain
with respect to the FERM domain might be required for membrane binding, and this movement
could potentially contribute mechanistically to FAK activation. The current study was undertaken
to test the biochemical and biological significance of this observation.
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Materials and Methods
Molecular Biology
FAK mutants were created using a modified version of the Quickchange (Agilent)
mutagenesis protocol using the viral vector pLUdr containing wild type avian FAK cDNA or the
expression vector pGEX-KG containing wild type avian FAK catalytic domain as a template. Primers
for site-directed mutagenesis were designed to substitute alanine for lysine or arginine residues at
the sites of interest. Sequence analysis verified the presence of the intended mutations and that no
unintended mutations were present. (ACGT Inc.).
Cell Culture and Imaging
Human embryonic kidney (HEK) 293T cells and mouse embryonic fibroblasts (MEFs)
(ATCC) were maintained in Dulbecco’s modiﬁed Eagle’s medium (DMEM) containing 10% fetal
bovine serum (FBS) and 1% Streptomycin/Penicillin. HEK 293T cells were co-transfected with the
pLUdr-FAK vectors and the PAX2 and VSVG viral packaging vectors using Turbofect (Thermo
Fisher) according to the manufacturer’s instructions. Media containing virus was collected at 24,
48, and 72 hours. Media was pooled and filtered using a 0.45 µm filter (Milipore). fak-/- MEFs
(ATCC) were incubated with the resulting virus-containing supernatant for 6 hours and selected
with puromycin after 24 hours. Puromycin selection was carried out for five days.
For immunofluorescence experiments, cells were plated on fibronectin coated coverglass
overnight. Cells were ﬁxed in 3% formaldehyde for 15 min and permeabilized with 0.4% Triton X100 for 10 min. FAK was detected using the BC4 anti-FAK antibody and an Alexa Flour488
(Invitrogen) conjugated anti-rabbit secondary antibody as previously described [22]. Paxillin was
detected using an anti-paxillin antibody (BD Biosciences) and an Alexa Fluor 488 conjugated antimouse secondary antibody (Invitrogen). Cells were visualized by using a Zeiss Fluorescent Axio
Imager Z2 microscope with Zeiss 63x (N.A. 1.40) objective. Images were taken with an AxioCam
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MRm Rev.3 camera with identical exposure times. Images were analyzed using ImageJ. Individual
cells were selected and the contrast inverted. The threshold of this overlay was set to restrict
analysis to focal adhesions. The area of focal adhesions was calculated using the Analyze Particles
function. The scale was set so that pixel area was converted into µM2.
To measure cell spreading, fak-/- cells expressing wild type or mutant FAK were transfected
with GFP-paxillin to allow live cell imaging. Cells were plated on fibronectin coated imaging glass
dishes. After a five minute incubation period to allow attachment, dishes were placed in an
environmental chamber mounted onto a Nikon Swept Field confocal microscope. Cells expressing
GFP-paxillin were visualized using a Nikon 40x oil objective and images were taken at one minute
intervals with an exposure time of 200 msec for GFP. Background subtraction was performed. Cells
were outlined and cell diameters at each time point were recorded using the Nikon NIS Elements
analysis software.
To measure focal adhesion dynamics fak-/- cells expressing wild type or mutant FAK were
transfected with GFP-paxillin to allow identification of adhesions. Cells were placed on fibronectin
coated imaging glass dishes for 4 hours to allow for spreading defects between cell lines. Cells were
refed with imaging media and placed in an environmental chamber mounted on a Nikon Swept
Field confocal microscope. Cells were visualized utilizing a Nikon 60x oil objective and images
were taken at one minute intervals with an exposure time of 200 msec over an hour. Background
subtraction was performed. Focal adhesions were analyzed utilizing the Focal Adhesion Analysis
Server [33,34]. This server allows the log-linear fitting method determination of assembly and
disassembly phase length in which models are fit to all assembly and disassembly phases greater
than or equal to a length of 2 minutes, as described in Webb et al. [35].
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Protein Analysis
Cells were lysed in ice-cold modiﬁed radioimmunoprecipitation assay (RIPA) buffer (50 mM TrisHCl [pH 7.3], 150 mM NaCl, 1% IGEPAL, 1% Nonidet P-40, 0.5% deoxycholate, 0.5% aprotinin, 1 mM
phenylmethylsulfonyl fluoride, 1.5 mM vanadate). Lysates were clariﬁed, and protein
concentrations were determined using the bicinchoninic acid assay (Pierce). Lysates were boiled in
Laemmli sample buffer (60 mM Tris-Cl pH 6.8, 2% S.D.S, 10% glycerol, 5% β-mercaptoethanol,
0.01% bromophenol blue) and 15 μg of total protein was analyzed by Western blotting. An anti-FAK
antibody (4.47 - Millipore), an anti-phosphotyrosine antibody (4G10 - Millipore) and anti-FAK
phosphospecific antibodies (PTyr397, PTyr577 and PTyr861 - Invitrogen) were used as primary
antibodies for Western blotting. Horseradish peroxidase (HRP) conjugated anti-mouse and antirabbit secondary antibodies (Millipore) were used to detect FAK expression and phosphorylation
levels using Immobilon Western HRP chemiluminescence substrate (Millipore). Quantification of
blots was performed with ImageJ (http://rsb.info.nih.gov/nih-image). Developed films were
scanned as TIFF images in 8-bit grayscale format at 600 dpi. The lanes were defined using the
rectangular select tool and the Analyze → Gels → Select First Lane/Select Next Lane function.
Densitometry measurements were calculated using Analyze → Gels → Plot lanes. Band peak was
defined from background using the straight line tool then the area of the band peak was calculated
using

the

Wand

tool.

(Protocol

can

be

found

at

http://rsb.info.nih.gov/nih-

image/manual/tech.html#analyze.) Band intensities of the phosphotyrosine blots were divided by
the band intensities of the FAK blots and all wild type samples were normalized to one.
Protein purification
The expression of recombinant protein in Escherichia coli BL21 (Codon Plus) cells (Agilent)
was induced at an absorbance (OD) at 600 nm of 0.8 to 1.0 by the addition of 0.1 mM IPTG
(isopropyl-β-d-thiogalactopyranoside), and cells were grown for an additional 8 h at 22°C. The cells
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were harvested and frozen at −20°C. Cell pellets were thawed and resuspended in lysis buffer (20
mM Tris [pH 8.0], 100 mM NaCl, 1 mM ethylenediaminetetraacetic acid, 4% Triton X-100, 10%
sarkosyl, 10 mM 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS)). Lysis
buffer was supplemented with the addition of protease inhibitors at a final concentration of 1 mM
phenylmethylsulfonyl fluoride, 1 mM benzamadine, 10 μg/ml of leupeptin, 10 mg/ml of lysozyme,
and 1 mg/ml of DNase. The resuspended cells were lysed by sonication on ice. After clarification,
supernatants were loaded onto a glutathione sepharose column. Following extensive washing with
Tris buffered saline (pH 7.4), protein was eluted with a buffer containing 50 mM Tris [pH 8.0], 150
mM NaCl and 50 mM glutathione. Elution fractions were concentrated using Ultra-4 centrifugal
filter units (10 kDa NMWL) (Amicon).
Lipid Binding
Lipid binding was assessed by co-sedimentation with large, unilamellar vesicles (LUV). The
ability of the catalytic domain to bind PI(4,5)P 2 was analyzed using lipid vesicles containing
50%PC/40%PE/10% PI(4,5)P 2 (experimental) or 60%PC/40%PE (control). Vesicles were prepared
by mixing chloroform dissolved phospholipids (Echelon) in appropriate ratios. The mixture was
dried using a speed vacuum for 15 minutes. The dried lipid cake was suspended into a lipid binding
buffer (20 mM HEPES [pH 7.5], 2 mM dithiothreitol, 250 mM NaCl) to a final concentration of 2.5
µg/ul [36]. The lipid suspension containing large multilamellar vesicles (LMV) was passed eleven
times through a 100 nm filter using an Avanti mini-extruder set to ensure a homogenous suspension
of LUVs. Four micrograms of glutathione S-transferase (GST) fusion protein was incubated with
250 µg of lipid vesicles on ice for 1h. The mixtures were centrifuged at 100,000 x g for 1h at 4 C°. The
supernatants were collected, mixed with Laemmli sample buffer (60 mM Tris-Cl pH 6.8, 2% S.D.S,
10% glycerol, 5% β-mercaptoethanol, 0.01% bromophenol blue) and boiled. The pellets were
resuspended in Laemmli sample buffer and boiled. The samples were analyzed by S.D.S102

polyacrylamide gel electrophoresis (PAGE) and Coomassie blue staining. Quantification of gels
was performed with ImageJ (http://rsb.info.nih.gov/nih-image). Images of gels were converted to
TIFF images in 8-bit grayscale format at 600 dpi. The lanes were defined using the rectangular select
tool and the Analyze → Gels → Select First Lane/Select Next Lane function. Densitometry
measurements were calculated using Analyze → Gels → Plot lanes. Band peak was defined from
background using the straight line tool, then the area of the band peak was calculated using the
Wand

tool.

(Protocol

can

be

found

at

http://rsb.info.nih.gov/nih-

image/manual/tech.html#analyze.) Band intensities of the supernatant and pellet lanes were
divided by the sum of the band intensities of the supernatant and pellet.
For anisotropy experiments purified GST fusion proteins were incubated with BODIPY
(dipyrromethene boron difluoride)-labeled phosphoinosotides with C6-acyl chains (Echelon).
Increasing concentrations of purified protein were added to 12.5 nM fluorescent phosphoinositide
in buffer containing 20 mM HEPES [pH7.5], 150 mM NaCl, and 5 mM β-mercaptoethanol.
Anisotropy measurements were taken at 37°C using a Flourlog spectroflourometer equipped with
Glan-Thompson polarizers with FluorEssence software (HORIBA Jobin Yvon). Specific binding of
the catalytic domain was determined by subtraction of binding of GST alone. Binding curves and
dissociation constants were determined using the Prism 5.0 statistical analysis software
(GraphPad).
Kinase Assay
White low-volume 96-well polystyrene plates (PerkinElmer) were used for the ADP-Glo
assay. Four µg of kinase was mixed with 25 μL of kinase buffer (5 mM MgCl2, 5 mM MnCl, 50 mM
TrisHCl pH 7.4), 2.5 µg Poly-Glu-Tyr, and 25 mM ultrapure ATP (Promega). All reactions were
carried out in triplicate. Blank wells lacked enzyme but did include kinase buffer, substrate, and
ATP. The plates were covered and the reactions were carried out at room temperature (RT) for up
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to 120 min. Reactions were stopped with the addition of 50 μL ADP-Glo reagent (Promega). After a
40-min incubation at RT, 50 μL of Kinase Detection Reagent (Promega) was added and the plates
were incubated for another 40 min at RT. Plates were read on a BioTek Synergy 4 plate reader with
a sensitivity of 150 and an integration time of 1 s per well. For kinase reactions involving lipids, 8 μg
of kinase was preincubated with 25 μL of lipid vesicle solution at RT prior to addition of 25 μL of
kinase buffer with 5 µg poly-Glu-Tyr, 25 mM ATP. Data were plotted using Prism 5.0 statistical
analysis software (GraphPad).
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Results
Catalytic Domain Residues are Required for Maximal FAK Phosphorylation in vivo.
To assess the physiological relevance of the catalytic domain basic residues implicated in
phospholipid binding by the molecular modeling simulations, select residues were substituted with
alanine and engineered in the full length FAK cDNA in the pLUdr lentiviral vector (Figure 1). Since
Arg508, Arg514 and Lys515 are located in a single alpha helix (αD), a mutant containing alanine
substitutions for these residues was engineered (R508A/R514A/K515A). As Lys621 and Lys627 are
located within the same loop between αF and αG of the FAK catalytic domain, another mutant with
alanines substituted for these two residues was created (K621A/K627A). Finally, since Arg508 and
Lys621 are in close proximity in the three-dimensional structure of the catalytic domain, a mutant
with alanine replacing these two residues was created (R508A/K621A) (Figure 1B). The
R508A/R514A/K515A, R508A/K621A, and K621A/K627A mutants were expressed in fak-/- mouse
embryo fibroblasts (MEFs). Populations of MEFs expressing each construct were lysed and lysates
were analyzed by Western blotting for FAK expression and FAK phosphorylation (Figure 2A).
Tyrosine phosphorylation levels were normalized to FAK expression levels and compared to WT
FAK phosphorylation levels. FAK phosphorylation at Tyr397 and Tyr577 was significantly decreased
in the R508A/K621A and K621A/K672A mutants (Figure 2 B&C). The R508A/R514A/K515A mutant
exhibited a reproducible reduction in tyrosine phosphorylation at these sites, but the decrease did
not reach statistical significance. All three mutants showed a reproducible reduction in
phosphorylation at the Tyr861 site, with the R508A/K621A and R508A/K514A/K515A mutants
showing a significant decrease (Figure 2 D). Autophosphorylation at Tyr397 is one of the most well
defined steps in FAK activation and is necessary for Src binding and subsequent phosphorylation
of Tyr577 and Tyr861. The reduction in phosphorylation of these sites is indicative of reduced FAK
activation and demonstrates that these mutants are less responsive to upstream signals.
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As localization of FAK is required for correct regulation, the subcellular localization of the
FAK mutants was assessed by immunofluorescence to ensure the phosphorylation defects seen
were not due to mislocalization. The fak-/- MEFs exhibited no FAK staining (data not shown), while
cells re-expressing wild type or mutant FAK exhibited staining with the anti-FAK antibody. The
FAK mutants localized to focal adhesions comparably to wild type (Figure 3). This indicates that
the reduced phosphorylation level of the FAK mutants is not attributable to poor localization.
Catalytic Domain Mutants Exhibit Impaired Biological Function
Knockout of FAK from cells leads to a variety of phenotypes associated with defects in focal
adhesion turnover, including an increase in focal adhesion size and decreased cell spreading. To
test the biological effectiveness of the catalytic domain mutants, focal adhesion size, focal adhesion
dynamics and cell spreading were measured.
fak-/- MEFs exhibit an increase in focal adhesion size and re-expression of wild type FAK
rescues this phenotype [37]. To determine if the catalytic domain mutants were capable of rescuing
this phenotype, cells were immunostained for paxillin, a focal adhesion marker, and visualized by
immunofluorescence. As previously published, the fak-/- MEFs exhibited large focal adhesions and
cells re-expressing wild type FAK contained much smaller focal adhesions [38] (Figure 4A & B). The
focal adhesions in cells expressing FAK mutants appeared to have an intermediate focal adhesion
phenotype, i.e. paxillin-positive focal adhesions in cells expressing FAK mutants are smaller than
those in fak-/- cells, but larger than the focal adhesions in wild type FAK-expressing cells (Figure
4C,D,E). Thus, the mutants appeared partially defective in controlling focal adhesion size.
To confirm this qualitative observation, the average area of the focal adhesions in each of
the cells was calculated (Figure 4F). As expected, cells re-expressing wild type FAK had significantly
smaller focal adhesions (0.85 ± 0.27 µm) than fak-/- cells (2.71 ± 0.05 µm). Cells re-expressing the
R508A/K621A mutant exhibited significantly larger focal adhesions than cells re-expressing WT
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FAK (1.43 ± 0.13 µm, P<0.01). Cells expressing the other two FAK mutants, R508A/R514A/K515A and
K621A/K627A, also exhibited a larger average focal adhesion area than wild type re-expressing cells
(1.26 ± 0.08 µm and 1.20 ± 0.08 µm, P<0.05) (Figure 4). These size differences demonstrate that
these mutants are partially defective for transmitting downstream signals that control a biological
outcome regulated by the wild type FAK protein.
The role of FAK function in focal adhesion turnover is well established [39]. To assess the
role of catalytic domain residues in regulation of focal adhesion dynamics, focal adhesion stability,
assembly and disassembly rates were measured.

As R508A/K621A exhibited the largest defect on

focal adhesion size, this analysis was focused on this mutant. fak-/- MEFs stably expressing wild type
or R508A/K621A FAK were transfected with GFP-paxillin as a marker to monitor focal adhesion
assembly and disassembly. Images were collected at one minute intervals over two hours. Images
were analyzed through the Focal Adhesion Analysis Server (FAAS) [33]. Re-expression of wild type
FAK in fak-/- MEFs resulted in an increase in both the rate of assembly and disassembly resulting in
a stability time of 18.55 minutes, compared with 30.07 minutes for fak-/- MEFs (Table 1). Expression
of R508A/K621A modestly increased the focal adhesion assembly and disassembly rates and the
stability time of focal adhesions in these cells was 25.60 minutes. Thus, these basic residue
mutations impair normal FAK function in regulating assembly and disassembly of focal adhesions.

Table 1.: Summary of Results from Focal Adhesion Analysis Server
Cell Type

Assembly Rate (min-1)

Disassembly Rate (min-1)

Stability Time (min)

n (FA)

WT FAK

1.04 x 10 ± 0.035

-1

1.55x10 ± 0.017

18.55 ± 0.75

2064

FAK -/-

1.01 x 10-2 ± 0.0065

9.88x10-3 ± 0.008

30.07 ± 0.35

1285

2.97x10 ± 0.0046

25.60 ± 0.20

1775

-1

R508A/K621A 2.02x10 ± 0.0025
-2

-2

Since FAK activity is required for rapid cell spreading on fibronectin the ability of the
R508A/K621A mutant to promote cell spreading was also assessed [38]. fak-/- MEFs and cells re-
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expressing wild type FAK or R508A/K621A were transfected with GFP-paxillin to facilitate imaging.
Cells were trypsinized, plated on fibronectin coated coverslips and spreading was monitored by
time lapse video microscopy. Images were acquired every minute over a 2 hour period and
spreading of individual cells was measured by calculating cell area at each individual time point
(Figure 5). While MEFs re-expressing wild type FAK spread rapidly on fibronectin coated coverslips,
fak-/- cells took significantly longer to spread. Cells expressing R508A/K621A exhibited a dramatic
defect in cell spreading, comparable to the spreading defect exhibited by the fak-/- MEFs. These
results support the hypothesis that the basic residues on the catalytic domain of FAK are required
for biological function.
FAK Catalytic Domain Binds Phospholipids
Molecular dynamics simulations suggest that five basic residues in the catalytic domain of
FAK can dock to PI(4,5)P 2 head groups in the membrane [28] (Figure 1). To experimentally test this
hypothesis, the catalytic domain of FAK was expressed as a GST fusion protein and binding to
PI(4,5)P 2 was measured. Two different experimental approaches were utilized to measure lipid
binding, lipid vesicle co-sedimentation and fluorescence anisotropy. For lipid vesicle cosedimentation studies, large unilamellar lipid vesicles composed of 60% phosphatidylcholine (PC)
and 40% phosphatidylethanolamine (PE) were prepared as control vesicles and experimental
vesicles containing 10% PI(4,5)P 2 /50%PC/40%PE were made. GST or GST catalytic domain fusion
proteins were incubated with lipid vesicles for 1 hour on ice prior to vesicle sedimentation at 100,000
x g for 1 hour at 4oC. The amounts of GST and fusion protein partitioning into the pellet (lipid
bound) and supernatant (free) was determined by analyzing the two fractions by S.D.S-PAGE and
Coomassie blue staining. In the absence of lipid vesicles, each protein was exclusively found in the
supernatant (Figure 6A). In the presence of PC/PE vesicles, a fraction of the GST catalytic domain
fusion protein co-sedimented with the vesicles (28.2%). A larger fraction of the GST catalytic
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domain fusion protein (88.8%) co-sedimented with PI(4,5)P 2 containing vesicles (Figure 6). Under
all conditions, the GST control remained in the supernatant fraction. To determine the role of the
catalytic domain basic residues in vesicle binding, a mutant containing alanine substitutions for all
5 of these residues (Arg508, Arg514, Lys515, Lys621 and Lys627) was engineered (called RK5A) and
analyzed for co-sedimentation with lipid vesicles. This GST mutant catalytic domain fusion protein
was found in the supernatant in the absence of lipid vesicles. In the presence of PC/PE lipid vesicles,
a fraction of the mutant fusion protein co-sedimented with the vesicles (20.6%). A similar fraction
of the mutant fusion protein co-sedimented with PI(4,5)P 2 -containing vesicles (27.6%) (Figure 6).
These findings demonstrate that the FAK catalytic domain exhibits some binding to PC/PE vesicles,
that binding is increased in the presence of PI(4,5)P 2 , and that the basic residues on the catalytic
domain play a role in binding to PI(4,5)P 2 .
PI(4,5)P 2 binding was further validated using fluorescence anisotropy. GST and the GST
catalytic domain of FAK were incubated with BODIPY-TMR labeled short acyl chain (C6) PI or
PI(4,5)P 2 and anisotropy measured. Specific binding (ΔmP of GST-catalytic domain minus ΔmP of
GST ΔmP of GST) was plotted against protein concentration and Kd for binding was calculated (Kd
=15.7+/-6.5 µM) (Figure 7). The wild type catalytic domain did not specifically bind PI and the RK5A
mutant showed no specific binding to PI(4,5)P 2.
FAK Catalytic Domain Mutants Exhibiting Biological Defects are Defective for Phospholipid Binding.
To determine if the FAK mutants exhibiting defects in the control of biological processes
also exhibited defects in phospholipid binding, the R508A/R514A/K515A, K621A/K627A, and
R508A/K621A mutations were engineered into the GST-catalytic domain construct. Short acyl chain
(C6) BODIPY labeled PI(4,5)P 2, was chosen to assess the ability of these mutants to bind
phospholipids using fluorescence anisotropy. The R508A/R514A/K515A and K621A/K627A mutants
each bound to the short acyl chain PI(4,5)P 2 (K d = 16.4 ± 3.2 and 20.8 ± 2.7 µM respectively) (Figure
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7 C, D). In contrast, the R508A/K621A mutant was defective for PI(4,5)P 2 binding (K d > 200
µM)(Figure 7E). Thus, the mutants exhibiting modest biological defects were capable of binding
PI(4,5)P 2, whereas the mutant with the severest defect in controlling biological responses was
deficient in binding PI(4,5)P 2 . These results support a role for these group II basic residues in the
phosphatidylinositol phosphate binding activity of the catalytic domain and demonstrate that
Arg508 and Lys621 are particularly important for phosphatidylinositol phosphate binding and
regulating biological outcomes at the cellular level.
FAK Catalytic Domain Interacts with Multiple Phosphatidylinositol Phosphates
To test the specificity of the lipid interaction, the binding of wild type and RK5A GST-fusion
proteins to phosphatidylinositol, PI(4)P, PI(4,5)P 2 , and PI(3,4,5)P 3 was analyzed. Purified GST
catalytic domain fusion proteins were titrated into a solution of BODIPY-labeled phospholipids
with C6-acyl chains, and anisotropy was measured. Phosphatidylinositol with C6-acyl chains and
purified GST were used as controls. Differences in anisotropy of each BODIPY-labeled phospholipid
at 100 and 200 µM of each protein were compared by ANOVA and a Tukey’s posttest (see
Supplemental Table 1). The wild type catalytic domain showed significant binding to all
phosphatidylinositol phosphates, but not PI, compare to the GST control and RK5A. Compared
with the PI control, binding of PI(4,5)P 2 and PI(3,4,5)P 3 to the wild type catalytic domain was
significant, while binding of PI(4)P approached, but did not reach significance. To calculate binding
affinities, anisotropy was plotted against protein concentration and binding to GST was subtracted
as background binding. The K d of the wild type catalytic domain for PI(4,5)P 2 was calculated to be
12.9 ± 2.3 µM (Figure 8B). Specific binding of wild type to PI(4)P and PI(3,4,5)P 3 resulted in K d
values of 11.7 ± 13.7 µM and 16 ± 9.2 µM respectively. To determine if the observed interaction with
the short acyl chain PI(4,5)P 2 required the basic residues implicated in binding to PI(4,5)P 2 containing vesicles, the RK5A mutant was analyzed. This mutant exhibited binding similar to GST
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with all phospholipids tested (K d >200 µM) (Figure 8C). These results demonstrate that the catalytic
domain of FAK exhibits phosphatidylinositol phosphate binding, but that it does not discriminate
between different phosphatidylinositol phosphate species.
Phospholipid Binding and Catalytic Activity
Although it was unlikely that substitution of basic residues on the surface of the catalytic
domain with alanine residues would perturb enzymatic activity, catalytic activity of the wild type
and RK5A mutant fusion proteins was measured. Four micrograms of protein were incubated in
kinase reaction buffer containing poly(Glu,Tyr) as substrate and the generation of ADP was
monitored using the ADP-Glo assay. GST alone showed no activity while the wild type GST catalytic
domain demonstrated activity. The catalytic activity of the RK5A mutant was identical to the
activity of the wild type fusion protein (Figure 9A). Therefore the mutations did not alter the
enzyme activity of the catalytic domain and by inference did not perturb the structure of the
domain.
An intriguing possibility is that lipid binding to the catalytic domain might directly
modulate catalytic activity. To test this hypothesis, the GST catalytic domain fusion protein was
incubated with PC/PE vesicles or PC/PE vesicles containing PI(4,5)P 2 in vesicle binding buffer, prior
to performing the kinase assay. The catalytic domain exhibited the same activity in the presence of
buffer only, PC/PE vesicles and PC/PE vesicles containing PI(4,5)P 2 (Figure 9B). These results
demonstrate that association with lipid vesicles has no impact upon the enzymatic activity of the
isolated catalytic domain.
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Discussion
In addition to studies demonstrating PI(4,5)P 2 binding to the basic sequence on the F2 lobe
of the FERM domain [24,25], a recent computational modeling study identified other potential
PI(4,5)P 2 interaction sites on the catalytic domain [28]. We have validated PI(4,5)P 2 binding to the
catalytic domain using both lipid sedimentation and fluorescence anisotropy approaches and
mutation of the basic residues proposed to bind PI(4,5)P 2 impaired catalytic domain binding to
PI(4,5)P 2 . While identified basic residues did mediate this interaction, the catalytic domain of FAK
also demonstrated binding to PI(4)P and PI(3,4,5)P 3 . Thus the basic residues on the surface of the
catalytic domain facilitate association with multiple phosphatidylinositol phosphates rather than a
specific phosphorylated species.
Interestingly, mutation of a pair of spatially proximal basic residues, R508A/K621A, was
sufficient to dramatically impair phosphatidylinositol phosphate binding. This mutant exhibited
defects in tyrosine phosphorylation in vivo and in the control of biological events regulated by FAK.
These results implicate these catalytic domain basic residues in FAK function in vivo, which can at
least partially be attributed to defects in phospholipid binding. Mutation of other subsets of the
catalytic domain basic residues had little impact on phosphatidylinositol phosphate binding in the
fluorescence anisotropy assay and only partially impaired the control of FAK-dependent biological
responses in cells. The R508A/R514A/K515A and K621A/K627A mutants could exhibit a more subtle
phospholipid binding defect, not detected in the fluorescence anisotropy experiments, or a defect
in association with a novel protein or ligand. . All five of these residues are conserved, in avian,
murine and human FAK sequences. R508, K621 (the most important residues for biological
function) and K627 are also conserved in Drosophila melanogaster. Interestingly, only one of these
residues (K515) is conserved in the murine and human sequences of protein tyrosine kinase 2
(PYK2), a protein highly related in sequence to FAK [40]. In total, these observations support the
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importance of these basic residues in the biochemical and biological function of FAK and suggest a
function that is unique to FAK and not shared by Pyk2 [40] [41,42].
Phosphatidylinositol phosphate binding is a key component in many cellular signaling
pathways and can serve to alter subcellular localization and/or enzymatic activity. A very well
characterized example is the PI(3,4,5)P 3 /Akt signal transduction pathway, where the generation of
PI(3,4,5)P 3 at the membrane recruits protein kinase D and Akt to the membrane via their PH
domains facilitating activation of Akt [43]. The mechanism of PH domain binding to phospholipids
is well established. PH domains accommodate the headgroup of phosphatidylinositol phosphates,
for example PI(3,4,5)P 3 and PI(4,5)P 2 , in a basic pocket that recognizes charge and shape to provide
phospholipid binding specificity [44,45] A number of other lipid binding domains, e.g. FYVE and
ENTH domains, similarly use a basic pocket to bind phosphoinositides [46,47]. In contrast, there
are specific examples of phosphatidylinositol phosphate binding to basic residues exposed on the
surface of a domain, rather than within a binding pocket. Examples of this binding mechanism
include the FERM domain of FAK, which binds PI(4,5)P 2 through interactions with basic residues
along a surface exposed α-helix [22], and the tail of vinculin, which interacts with PI(4,5)P 2 through
interactions with basic residue side chains projecting from its surface [48]. Other modular domains
exhibit phospholipid binding sites that do not contain a basic binding pocket. For example many
phosphotyrosine binding (PTB) domains have phospholipid binding sites separate from their
phosphotyrosine binding sites. The phospholipid binding motif in PTBs is not a conserved sequence
but an electrostatic feature defined as a “basic crown” [49], and mutation of basic residues in these
regions can abrogate lipid binding [50]. Additionally, a recent study showed that many Src
homology 2 (SH2) domains bind plasma membrane lipids with a high affinity and that binding
occurs through alternate cationic patches (ACPs) [51]. ACPs bind several membrane lipid molecules
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simultaneously while leaving the phosphotyrosine binding site of the SH2 domain accessible for
ligand binding.
The interaction of the FAK catalytic domain with the membrane via basic residues on the
side of the catalytic domain is envisioned to leave the ATP and substrate binding sites accessible
for catalytic activity. A few studies have address the structure of substrates in complex with kinase
domains using peptides to mimic the interaction with the active site. In these structures, the
substrates adopt an extended conformation [52–55]. Further, computational analysis reveals that
phosphorylation sites reside in regions of proteins that are predicted to be disordered [56]. A main
phosphorylation target of FAK catalytic activity is an autophosphorylation site, tyrosine 397 in the
flexible linker between the FERM and catalytic domains [57]. In the autoinhibitied conformation,
the linker region containing tyrosine 397 binds to the FERM domain. Biochemical analysis reveals
that in this conformation tyrosine 397 is a poor site for phosphorylation, compared with an
extended conformation, suggesting that release of the linker from the FERM domain may be
required for phosphorylation [19]. There is no structural information about the linker in any context
other than the autoinhibited conformation, and predictions suggest that it is unstructured. A
second substrate is the FAK binding protein, paxillin. The N-terminal half of paxillin, which is the
location of its phosphorylation sites, is predicted to be intrinsically disordered. Since authentic FAK
substrates are phosphorylated in disordered regions, we expect that these sites can access the FAK
active site, even when adjacent to the membrane.
The phosphatidylinositol phosphate binding site on the catalytic domain, which lies on the
side of the catalytic domain near the juncture of the small and large lobes of the kinase is at a site
that could potentially regulate catalytic activity. The interaction of other ligands with the catalytic
domain of kinases can alter activity. For example, binding of cyclin to cyclin-dependent kinases
alters the small lobe of the catalytic domain to create a catalytically competent structure [58]. Small
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ligands can also impact activity. For example, copper binding to the catalytic domain of MEK1 is
required for enzymatic activity [59]. While these ligands bind on the opposite side of the kinase
domain relative to the phosphatidylinositol phosphate binding site on the FAK catalytic domain,
these precedents prompted an experiment to directly assess the impact of lipid binding upon
catalytic activity. The results demonstrated that lipid binding has no effect upon the activity of the
isolated FAK domain. These results are consistent with the conclusion drawn by Goni et al, that
phosphatidylinositol phosphate binding does not directly regulate catalytic activity [25]. Since lipid
binding does not directly regulate the activity of the isolated catalytic domain, the observed
biochemical and biological defects associated with the phosphatidylinositol phosphate binding
mutant reflects a role in regulating function only in the context of the full length FAK protein.
Goni, et al. report lipid binding experiments with a construct containing the FERM and
catalytic domains of FAK, and the KAKTLRK mutant, which ablates the FERM domain basic patch,
does not exhibit binding despite the presence of the basic residues in the catalytic domain [25]. The
difference in results between studies could reflect differences in experimental conditions including
vesicle and buffer composition. Conversely, the different results might demonstrate that PI(4,5)P 2
engagement of the FERM domain basic patch is a requirement for catalytic domain binding to
phospholipids in the context of a larger construct, although such a requirement was not evident in
molecular dynamics simulations. Interestingly, phospholipid binding studies using the construct
containing the FERM domain and catalytic domain demonstrated cooperative binding [25]. This
could reflect oligomerization of FAK [25]. However, the cooperativity of binding could also be
explained by exposure of a second phosphatidylinositol phosphate binding site, i.e. the binding site
in the catalytic domain. The critical mechanistic event relieving autoinhibition resulting in FAK
activation remains to be conclusively demonstrated. PI(4,5)P 2 binding to the FERM domain is
required, but insufficient for FAK activation [25]. It is possible that upon FERM domain binding
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dissociation of the FERM and catalytic domains must occur prior to docking of the catalytic domain
to phosphatidylinositol phosphates. It has not been conclusively established how the FERM
domain/catalytic domain interface interactions are disrupted during FAK activation. An attractive
model for activation is a mechanical mechanism, since FAK activation is sensitive to stiffness of the
extracellular matrix outside the cell and requires the integrity of the cytoskeleton inside the cell
[60,61]. A recent molecular dynamics simulation has demonstrated that sufficient force can disrupt
the interaction between the FERM and catalytic domains without dissociating the FERM domain
from the PI(4,5)P 2 and without disrupting the alpha helical structure of the FERM and catalytic
domains [27]. Given this consideration, the catalytic domain interaction with phospholipids in the
membrane may serve to stabilize FAK in an active conformation, rather than participate in the
activation mechanism (Figure 10).
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Figure Legends
Fig. 1. Predicted PI(4,5)P 2 Binding Sites on the FAK Catalytic Domain. A) The surface view of the FERM
(pink) and catalytic (blue) domains in the autoinhibited conformation is shown. The linker
connecting the FERM and catalytic domains is colored gray. The F1, F2 and F3 lobes of the FERM
domain and the position of the PI(4,5)P 2 binding site are indicated. The basic residues in the large
lobe of the catalytic domain that are proposed to bind PI(4,5)P 2 are colored cyan. B) Ribbon
diagram of the catalytic domain of FAK demonstrating the location of the catalytic domain residues
proposed to bind PI(4,5)P 2 .
Fig. 2. Catalytic Domain Mutants of FAK Exhibit Defects in Phosphorylation. fak-/- MEFs expressing wild
type or mutant FAK proteins were analyzed to assess FAK tyrosine phosphorylation.
A) Representative Western blots of cell lysates probed with the FAK 4.47 antibody (FAK) or the
phospho-specific pTyr397, pTyr577, and pTyr861 antibodies are shown. B-D) Western blot
quantification was performed using ImageJ. Phosphorylation levels were normalized to FAK
expression levels. Mutant phosphorylation levels were compared to WT phosphorylation levels
using a one-way ANOVA analysis with a Dunnett’s post-test (n = 6 [pTyr397] or 10 [pTyr577 and
pTyr581] experiments, *= P < 0.05).
Fig. 3. FAK Catalytic Domain Mutants Localize to Focal Adhesions. fak-/- MEFs expressing wild type or
mutant FAK were plated on fibronectin coated cover slips overnight, fixed, permeabilized and
incubated with the anti-FAK 4.47 monoclonal antibody. Alexa Fluor 488-labeled anti-mouse
secondary antibody was utilized for visualization. Scale bar = 10 µm.
Fig. 4. FAK Catalytic Domain Mutants are Partially Defective in Controlling Focal Adhesion Size. A-E)
fak-/- MEFs expressing wild type or mutant FAK were plated on fibronectin coated cover slips, fixed,
permeabilized and incubated with an anti-paxillin monoclonal antibody. Alexa Fluor 488-labeled
anti-mouse secondary antibody was utilized for visualization. Scale bar = 10 µm. F. The average
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focal adhesion size in each cell line (+/- S.D.) was calculated using ImageJ (n > 30 cells for each
group, >20 focal adhesions measured per cell, over 3 experiments). Areas were then compared using
a one-way ANOVA with a Bonferroni Multiple Comparison post-test. The focal adhesion size in
cells expressing each of the FAK proteins was significantly different from the focal adhesion size
exhibited by fak-/- cells (P < 0.001). The focal adhesion size in cells expressing the mutant proteins
was also significantly different than the focal adhesion size in cells expressing wild type FAK (* P <
0.5, ** P < 0.01).
Fig. 5. The R508A/K621A Mutant is Defective at Promoting Cell Spreading. fak-/- cells and fak-/- cells
expressing wild type FAK or the R508A/K621A mutant were transfected with GFP-paxillin as a
fluorescent marker for time lapse imaging. Cells were trypsinized, taken into suspension and plated
on fibronectin coated imaging dishes. After 5 minute incubation to allow for attachment image
acquisition was initiated. Images were captured every minute for 120 minutes and cell diameters
were determined using Nikon NIS Elements analysis software. The change in average cell area (+/S.D.) for each cell type is plotted against time following initiation of imaging. (n = 18-20 cells over
4 experiments)
Fig. 6. FAK Catalytic Domain binds PI(4,5)P 2 Containing Lipid Vesicles. GST fusion proteins were
incubated in buffer alone or with large unilamellar vesicles comprised of 60%PC/40%PE (PC/PE)
or 50%PC/40%PE/10% PI(4,5)P 2 (PI(4,5)P 2 ). The samples were sedimented at 100,000 x g and the
supernatant (S) and pellet (P) fractions analyzed by S.D.S-PAGE and Coomassie blue staining (panel
A). The results of quantification of multiple experiments (n=6) is shown in panels B-D. The
partitioning of GST (panel B), the wild catalytic domain of FAK (panel C) and the RK5A mutant
catalytic domain (panel D) between supernatant (S) and pellet (P) fractions is shown. Gels were
analyzed using ImageJ and the fraction of each protein in the supernatant and pellet (+/- S.D.) was
plotted.
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Fig 7: FAK Catalytic Domain Binds Short Acyl Chain PI(4,5)P 2 . FAK catalytic domain GST fusion proteins
were incubated with BODIPY labeled short acyl chain (C6) PI or PI(4,5)P 2 and fluorescence
anisotropy measured as the change in mP. Specific binding was determined by subtraction of ΔmP
for GST alone from ΔmP for the GST catalytic domain fusion protein. The average change in mP
(+/- S.D.) as a function of protein concentration (n = 3 experiments) is shown. Specific binding of
the wild type catalytic domain (A) and fusion proteins containing the RK5A (B),
R508A/R514A/K515A (C), K621A/K627A (D) and R508A/K621A (D) mutations to PI(4,5)P 2 was
determined. The dissociation constants for the interaction between the catalytic domain variants
and PI(4,5)P 2 was calculated from the specific binding curves. Wild type K d = 15.7 ± 6.5 µM, RK5A
K d >200 µM, R508A/R514A/K515A K d = 16.4 ± 3.2 µM, K621A/K627A K d = 20.8 ± 2.7 µM,
R508A/K621A K d >200 µM.
Fig. 8. FAK Catalytic Domain Binds Multiple Phosphatidylinositol Phosphates. Fusion proteins were
incubated with BODIPY labeled short acyl chain (C6) phospholipids and florescence anisotropy
was measured. A) ΔmP for BODIPY labeled PI, PI(4)P, PI(4,5)P 2 and PI(3,4,5)P 3 in the presence of
100 µM GST, GST wild type catalytic domain and the RK5A mutant is shown (+/-S.D., n = 3
experiments). Specific binding (ΔmP of GST-FAK catalytic domain minus ΔmP of GST alone) of
GST wild type catalytic domain (B) and the RK5A mutant (C) is plotted versus concentration.
Specific binding to PI (circles), PI(4)P (squares), PI(4,5)P 2 (triangles) and PI (3,4,5)P 3 (inverted
triangles are shown). The dissociation constant of the wild type catalytic domain for each
phosphatidylinositol phosphate was calculated from the curves. PI K d >200 µM, PI(4)P K d =11.7 +/13.7 µM, PI(4,5)P 2 K d =12.9 +/- 2.3 µM, PI(3,4,5)P 3 K d =16 +/- 9.2 µM.
Fig 9. Lipid Binding Does Not Modulate Activity of Isolated FAK Catalytic Domain. The catalytic activity
of GST fusion proteins was determined using poly(Glu, Tyr) as a substrate. The generation of ADP
over time was measured using the ADP-GloTM assay protocol. A) The kinase activity of GST alone
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(circles), the GST catalytic domain fusion protein (WT, squares) and the GST RK5A mutant fusion
protein (triangles) were measured. The average concentration of ADP (+/- S.D.) generated in each
reaction is plotted versus time (n = 3). Specific activities were calculated for both WT and RK5A
proteins by taking the amount of product produced over a 5 minute period of time during the initial,
linear portion of the reaction divided by time, divided by mass of fusion protein. This resulted in a
specific activity of 1.025 +/- 0.002 nmol/min/mg for GST-WT and 0.913 +/- 0.004 nmol/min/mg for
GST-RK5A. B) WT catalytic domain was pre-incubated in lipid sedimentation buffer (squares),
buffer

containing

60%PC/40%PE

vesicles

(triangles),

or

buffer

containing

50%PC/40%PE/10%PI(4,5)P 2 vesicles (circles) for one hour prior to performing the kinase assay.
The average ADP concentration (+/- S.D.) generated in each reaction is plotted versus time (n = 3)
Specific activities were calculated for all conditions by taking the amount of product produced over
a 5 minute period of time during the initial, linear portion of the reaction divided by time, divided
by mass of fusion protein. This resulted in a specific activity of 0.460 +/- 0.004 nmol/min/mg for
buffer containing 60%PC/40%PE vesicles and 0.543 +/- 0.006 nmol/min/mg for buffer containing
50%PC/40%PE/10%PI(4,5)P 2 vesicles.
Fig 10. Proposed Model of FAK activation. A) FAK in its autoinhibited conformation can dock to
PI(4,5)P 2 (black) via the basic sequences in the FERM domain (black star in light gray domain). The
interaction between the FERM and catalytic domains (dark gray) is disrupted via a poorly defined
mechanism (B), allowing the rotation of the catalytic domain and docking to membrane
phospholipids via the basic sequences in the catalytic domain (white star) (C).
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CHAPTER 4: Conclusions
Focal adhesion kinase is involved in many physiological processes that are essential to
development of a multichambered heart and fully developed central nervous system. Additionally,
with its role in cell migration it is necessary for wound healing (REF). Because of its roles in cell
survival, proliferation, and motility FAK signaling is involved in many types of cancer (REF). As
such, FAK activity needs to be tightly controlled. However, the mechanism for activation has yet to
be fully determined.
FAK has three structured domains that contribute to the spatial control of activation. The
C-terminal structured domain is the focal adhesion targeting (FAT) domain [1]. This domain is
responsible for the localization to focal adhesions through interaction with paxillin [2]. Without
localization to the focal adhesions FAK activation does not occur at any meaningful level. The Nterminal FERM regulates catalytic activity through an autoinhibitory conformation in which it folds
over the active site of the kinase domain [3]. This conformation not only obscures the ATP and
substrate binding sites but also sequesters the Y397 autophosphorylation site in the linker between
the FERM and kinase domains through an antiparallel β-sheet formation. The F2 subdomain of the
FERM domain contacts the C-lobe of the kinase domain, at this site F596 in the kinase domain
inserts into a hydrophobic pocket in the FERM domain formed by Y180, M183, V196 and L197 [3].
Mutation of Y180 and M183 to alanine creates a constitutively active FAK, emphasizing the
importance of these areas for maintenance of the autoinhibited conformation [4]. Additionally, a
ridge of basic residues on the F2 subdomain,

KAKTLRK221, binds to acidic ligands such as

216

phosphotyrosine and PI(4,5)P 2 [4,5]. This allows for temporal control of FAK signaling as these
interactions allow response to upstream activating signals. Through an unknown mechanism this
ligand binding can trigger the release of the catalytic domain and exposure of Y397 and the ATP
and substrate binding sites. This allows phosphorylation of Y397 which acts as the docking site for
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Src. Src then phosphorylates the activation loop of the kinase, increasing catalytic efficiency, and
tyrosines in the region between the kinase domain and the FAT domain. This series of activation
steps leads to a fully active kinase with several binding sites, enabling a scaffolding function. The
main question in this activation mechanism is how autoinhibition is released, as without the release
of autoinhibition both catalytic and scaffolding functions cannot occur at their full efficiency. This
dissertation set out to elucidate the molecular interactions that lead to a release of autoinhibition
upon stimulation through investigation of key residues on the FERM and kinase domains.
Focal adhesion kinase is over expressed in many cancers and this overexpression is linked
to poor prognosis. While the mutation rate for FAK is low, several mutations have been identified
in the COSMIC database (http://cancer.sanger.ac.uk/cosmic ). The initial stage of this investigation
explored the effects of some of these single amino acid mutations found in patient tumor samples.
While the mutation rate of FAK is low, there was a high potential that these mutations could lead
to a dysregulated FAK molecule. Any effect caused by these mutations could provide insight into
alternative mechanisms of activation. Mutations falling with in the FERM domain, linker, and
kinase domain were chosen as they were most likely to disrupt regulation. The first mutation,
F147C, is located in the FERM domain, and could potentially disrupt the arrangement of the three
FERM subdomains. The second, D402V, is located in the linker, this mutation has the potential to
either disrupt the β sheet formed with the FERM domain or disrupt autophosphorylation at Y397.
The final mutation from the COSMIC database analyzed was A590V. This mutation is within the
kinase domain at the C-terminal end of the activation loop. This is part of the conserved APE
sequence, a region rich in mutations in cancer associated kinases [6]. In biochemical assays
measuring Y397 phosphorylation and catalytic activity F147C, and D402V were indistinguishable
from wild type. In these assays the A590V mutant appeared catalytically dead. To assess the effect
these mutants had on the autoinhibitory conformation they were analyzed utilizing a FRET based
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biosensor. These results mimicked the biochemical data. F147C and D402V showed similar FRET
levels as the wildtype biosensor and the A590V mutation lacked YFP emission signal indicating an
improperly folded kinase domain. Overall these results work to further classify FAK in the context
of cancer. There are two causes of aberrant kinase activation in cancer. The first are kinases that
are mutated, like BRAF and TGFBR1 [6]. The second type, like HER2 and BRK, are kinases that are
overexpressed [6,7]. The results of these mutation studies put FAK firmly in the overexpression
category.
The second stage of investigation involved the rational design of mutants based on the
crystal structures of the FERM domain and the FREM-kinase domains in the autoinhibited
conformation. Special attention was given to the area where the FERM F2 subdomain and the C
lobe of the kinase contact each other. Here F596 on the kinase domain fits into a hydrophobic
pocket created by Y180, M183, V196 and L197 on the FERM F2 subdomain. Previous studies
established that mutations of Y180, M183, and F596 can disrupt the formation of the autoinhibited
structure [3,4]. On the apex of the F2 subdomain there is a ridge of basic residues, 216KAKTLRK221 [8].
This ridge is important for the maximal activation of FAK and binds phospholipids [4,9]. The alpha
helix adjacent to the

KAKTLRK221 helix sits directly above Y180 and M184. This helix contains a
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series of basic residues R184, K190, K191. A notable feature of these residues is their side chains and
the peptide backbone adopt different conformations in the two crystal structures available. Based
on this flexibility it was hypothesized that these residues may play a role in FAK activation, most
likely through a change in conformation that would aid in the release of the kinase domain.
Mutation of these residues in the FRET based biosensor did not lead to a significant change in FAK
activation as measured by autophosphorylation. The mutants showed a slight change in basal level
FRET, indicating a more open FAK, however this change was not statistically significant.
Investigation of the change in FRET upon HGF stimulation showed no significant change in overall
140

FAK activity. However, these studies also showed a more variable response to HGF stimulation,
indicating there might be some dysregulation of the control of conformation. These results suggest
a minor role in controlling the autoinhibited conformation of FAK. While these residues are not
key for response to upstream elements through triggering the conformational change they may be
necessary for proper maintenance of the closed autoinhibited structure through contact with kinase
domain residues.
The 216KAKTLRK221 binds to both phospholipids and phosphotyrosine, potentially triggering
the release of autoinhibition and full FAK activation [4,5]. The RKK ridge while adjacent to the
KAKTLRK ridge is partially buried in the autoinhibited conformation but may still be able to bind
acidic ligands in concert with the KAKTLRK sequence. A recent study investigating the role of
phospholipids in FAK activation showed an 2.5 fold increase in affinity for PI(4,5)P 2 when the
interaction between the FERM and catalytic domains is destroyed by mutation of Tyr 180 and Met
183 to Alanine [10]. These mutations reduce the ability of FAK to hold the autoinhibited structure
and increase the activity level of FAK [4]. A more open FAK would decrease the amount of time
Arg 185, Lys 190, and Lys 191 are buried in the autoinhibited conformation. This could suggest that
this basic ridge is responsible for the additional PI(4,5)P 2 binding observed. Additionally, two
molecular dynamics simulations of FAK and PI(4,5)P2 interactions identify Lys 190 and 191 as
potential interactors with phospholipids [11,12]. The more recent of these two studies ran
simulations with both the FERM and FERM-Kinase crystal structures. Simulations run with just the
FERM domain suggest that residues buried in the autoinhibited conformation bind to the
membrane once exposed, rotating the FERM domain and reducing the likelihood of returning to
the autoinhibited structure [12]. Lys 190 and Lys 191 are among those implicated in these MD
stimulations. Lipid sedimentation studies with the RKK mutated FERM domain showed a 10%
defect in lipid binding. This decrease could account for the “nonspecific” binding observed when
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similar studies are performed with the KAKTLRK mutant. Overall the results shown in this thesis
and in other publications indicate that Arg 184, Lys 190, Lys 191 can interact with both the catalytic
domain and the membrane, contributing to both the maintenance of the autoinhibited
conformation and the maintenance of an open, catalytically active FAK. The results suggest that
while these residues are not critical for either the autoinhibited or open conformations they may
increase the stability in each.
The earlier molecular dynamics study show additional potential lipid binding sequences in
the catalytic domain of FAK [11]. This study indicated that a series of basic residues, Arg 508, R514,
K515, K621, and K627 were binding to the membrane through PI(4,5)P2 [11]. A second in silico study
confirmed the binding of Arg 508 and Lys 621 to PI(4,5)P 2 in both the autoinhibited and open
conformations [12]. These residues are all located on one face of the catalytic domain, suggesting
that this domain has a role in membrane binding in addition to the FERM domain. In vitro studies
were performed to confirm these in silico observations [13]. These studies confirmed that basic
residues on the side of the catalytic domain bind phospholipids. This binding was non-specific for
phosphatidylinositol phosphorylation variant, but the domain did not bind to phosphatidylcholine
or phosphatidylethanolamine. In vitro studies were followed up with in vivo studies to confirm
biological significance [13]. In cells mutation of two basic residues R508 and K621 caused decreased
FAK phosphorylation, an increase in focal adhesion area, and a defect in cell spreading. These verus
mundi studies proved that catalytic residues are needed for lipid binding. Additionally they showed
that mutation of only two residues, R508 and K621, can cause defects in cell spreading comparable
to FAK knockout. Additionally, this second lipid binding site on the FERM-kinase structure could
explain the avidity effect and lipid clustering observed in lipid binding studies performed with the
two domains together [10]. The fact that there is an increase in lipid binding when comparing the
FERM alone and FERM-kinase constructs but no difference between the FERM-kinase segment and
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full length FAK suggest the catalytic domain is the segment of FAK outside of the FERM domain
interacting with lipids.
The discovery of a second and, potentially, third membrane interaction site on the FERMkinase autoinhibited structure modifies previous understandings of FAK activation. Both in vivo
and in silico studies suggest that FAK is activated by mechanical force and acted as a mechanosensor
[14,15]. However, none of this evidence conclusively proves that FAK itself is a mechanosensor and
not simply downstream of other mechanosensory systems like integrins. Putting the FERM and
kinase domain membrane binding into a mechanosensory context; it is currently unclear if the
membrane binding functions actually trigger release of autoinhibition or whether they function to
hold the FERM and catalytic domains apart and produce sustained signaling. In a model where the
FAT domain is linked to the actin cytoskeleton through paxillin and the FERM domain binds to the
membrane through

KAKTLRK222, one can visualize force from cytoskeletal contraction pulling
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apart the autoinhibitory structure to trigger initial FAK signaling [14]. Upon a slight relaxation of
the cytoskeleton the kinase domain could then rotate and bind the membrane, and create
sustained signaling through preventing adoption of the autoinhibited conformation [13]. The two
in silico studies of FERM and catalytic domain lipid binding suggest that the catalytic domain or
other sites on the FERM domain bind more efficiently to PI(4,5)P 2 than the 216KAKTLRK222 sequence
[11,12]. This would suggest a different mode of activation than the current mechanosensory model.
An investigation of the binding strengths of both FERM, kinase, and FERM-kinase constructs for
phospholipids to assess binding affinity should be conducted. Fluorescence anisotropy studies are
a reliable method for determining quantifiable binding affinities and can yield data that would
further inform these conflicting models of FAK activation.
Another intriguing aspect of all of the proposed lipid binding sites on FAK is that none of
them create a binding pocket like other lipid binding domains (eg. FYVE or ENTH) [16,17]. However
143

the FERM domain lipid binding sites resemble the basic crowns found in some PTB domains that
also bind lipid and the scattered charged residues on the catalytic domain are similar to the
“alternate cationic patches” that enable some SH2 domains to bind the membrane [18]. So while
not unprecedented, these lipid binding motifs are unexpected. The lack of a binding pocket for
PI(4,5)P 2 likely explains the lack of specificity observed in lipid sedimentation studies [10,13].
Additionally, the

KAKTLRK222 sequence is important for direct interactions with the
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phosphorylated tail of the met receptor [5]. This lack of specificity may be advantageous, allowing
FAK to be activated by several different signaling pathways and differentially regulated in various
cell types.
This expanded view of FAK phospholipid binding suggests a model in which these basic
residues are necessary not for activation, but for maintaining the open conformation through
extramolecular contacts. This model suggests an effect on the length of time the FAK signal is
sustained by shifting the equilibrium to favor the open conformation when phosphoinositols are
plentiful. In the context of dysregulated FAK signaling, especially in cancer, the signaling and
regulation of lipid kinases is a vital component of aberrant FAK activity. The role of PI3K in cancer
signaling is well established [19]. In the case of FAK the phosphatase PTEN could also be important
for activation; mitigating its effect as a tumor suppressor by increasing levels of PI(4,5)P 2 . Both this
study and others show that while FAK has a generally nonspecific binding affinity towards PI
phosphorylation variants, the FERM and catalytic domains bind better to PI(4,5)P 2 [4,10,13].
PI(4,5)P 2 is abundant in focal adhesions and integrin signaling specifically results in PIP5KIγ
recruitment [20,21]. Previous studies have concluded that PIP5KIγ can contribute to cancer
progression through activation of gelsolin and N-cadherin junctions, and its inhibition can reduce
breast cancer metastasis [22,23]. PIP5 KIγ is now further linked to cancer progression through FAK
activation. The overexpression of FAK in many cancers is a poor prognostic indicator. This could
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be due to a scenario in which you have more PI(4,5)P 2 , to increase the sustained signaling of FAK
and more FAK to respond, creating a cell in which both proliferation and motility are increased
dramatically.
Because of its role in cancer progression FAK is an interesting target for therapeutics.
Currently there are several FAK inhibitors in clinical trials. Most inhibitors designed for FAK are
small molecule ATP-analogs that target the kinase domain [24–28]. In some cases these inhibitors
while effective, do not prove useful in clinical trials due to off target effects on other kinase domain
containing proteins [29,30]. Other approaches have been utilized in designing inhibitors for FAK.
Compound 14 is designed to bind at Y397, thus preventing Src binding and full activation of FAK
[31]. Another inhibitor targets the FAT domain and disrupts its interaction with paxillin [32]. The
design of multiple inhibitors to target multiple sites on FAK will increase the odds of a successful
therapeutic being developed [33]. The discovery of new areas on FAK that play a role in signaling
through lipid binding increase the potential sites for inhibitor development. The residues making
up the catalytic lipid binding site are not conserved in pyk2, FAK’s closest relative [13]. This
decreases the chance of the off target effects observes with ATP analog drugs. This research is the
very beginning step towards potential new inhibitors, with better characterization of the FAK
membrane interaction, the chances of a successful FAK inhibitor increase.
Overall, this work confirms that the catalytic domain of FAK binds to the membrane as
proposed in an in silico model. Additionally, this interaction is necessary for a fully functioning
FAK molecule and normal cell phenotype. Other portions of this dissertation suggest that the
FERM residues K190 and K191 may have an impact on lipid binding as well. More work needs ot be
completed to fully characterize both these interactions. The effect of these residues on the length
of time FAK stays in the active conformation needs to be assessed. Additionally the specificity of
these sites could be better characterized. There is a potential for either of these sites to bind to
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phosphotyrosines as well as phospholipids like

KAKTLRK221 does. This research will help to
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inform our understanding of FAK moving forward and may help establish a new model for signal
persistence if not release of autoinhibition.
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